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ABSTRACT OF DISSERTATION 
 
 
 
 
INSULIN ACTIONS ON HIPPOCAMPAL NEURONS 
Aging is the main risk factor for cognitive decline. The hippocampus, a brain 
region critical for learning and memory formation, is especially vulnerable to 
normal and pathological age-related cognitive decline. Dysregulation of both 
insulin and intracellular Ca2+ signaling appear to coexist and their compromised 
actions may synergistically contribute to neuronal dysfunction with aging. This 
dissertation focused on the interaction between insulin, Ca2+ dysregulation, and 
cognition in hippocampal neurons by examining the contributions of insulin to 
Ca2+ signaling events that influence memory formation. I tested the hypothesis 
that insulin would increase cognition in aged animals by altering Ca2+-
dependent physiological mechanisms involved in learning. The possible effects 
of insulin on learning and memory in young and aged rats were studied. In 
addition, the effects of insulin on the Ca2+-dependent afterhyperpolarization in 
CA1 pyramidal hippocampal neurons from young and aged animals were 
compared. Further, primary hippocampal cultures were used to examine the 
possible effects of insulin on voltage-gated Ca2+ channel activity and Ca2+-
induced Ca2+-release; mechanisms known to influence the AHP. 
We found that intranasal insulin improved memory in aged F344 rats. Young and 
aged F344 rats were treated with Humalog®, a short-acting insulin analog, or 
Levemir®, a long-acting insulin analog. The aged rats performed similar to young 
rats in the Morris Water Maze, a hippocampal dependent spatial learning and 
memory task. Electrophysiological recordings from CA1 hippocampal neurons 
revealed that insulin reduced the age-related increase in the Ca2+-dependent 
afterhyperpolarization, a prominent biomarker of brain aging that is associated 
with cognitive decline. Patch clamping recording from hippocampal cultured 
neurons showed that insulin reduced Ca2+ channel currents. Intracellular Ca2+ 
levels were also monitored using Fura-2 in response to cellular depolarization. 
Results indicated that a reduction in Ca2+-induced Ca2+-release from 
intracellular stores occurred in the presence of insulin.  
These results suggest that increasing brain insulin levels in aged rats may have 
improved memory by reducing the AHP and intracellular Ca2+concentrations. 
This study indicates a possible mechanism responsible for the beneficial effects 
of intranasal insulin on cognitive function absorbed in selective Alzheimer’s 
patients. Thus, insulin therapy may reduce or prevent age-related compromises 
to Ca2+ regulatory pathways typically associated with cognitive decline. 
 
KEY WORDS: Insulin, Aging, Cognition, Intracellular Ca2+, Ca2+ imaging, 
Whole-cell patch clamping 
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Chapter 1 Thesis Overview and Significance 
 
Aging, an inexorable natural process, often presents many challenges ranging 
from ambulatory to neuronal function. One of these challenges, age-related 
cognitive decline has received significant public attention because of its profound 
social and economic impact. A well-recognized mechanism contributing to age-
related cognitive decline involves dysregulation of intracellular calcium. Although 
Insulin has been recognized as the key hormone regulating cellular glucose 
metabolism, its downstream effects on learning and memory have only recently 
been found. Some evidence suggests that insulin undergoes age-related 
changes that ultimately influence calcium regulatory mechanisms in various 
brain regions, including the hippocampus, an area of the brain closely related to 
learning and memory. Thus, the negative impact of brain aging on cognitive 
function may be due to impaired insulin signaling and intracellular calcium 
homeostasis. However, the link between insulin and intracellular calcium in the 
context of cognitive decline with aging is not understood. This dissertation 
focused on the effects of insulin on memory and its underlying neuronal 
mechanisms. I specifically focused on studying1) the effects of insulin treatment 
on learning and memory in aged animals as well as 2) the effects of insulin on 
intracellular calcium regulation. Understanding the links between insulin and 
neuronal mechanisms involving hippocampal calcium processes may help 
develop therapeutic strategies to decrease complications associated with age-
related cognitive decline. 
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1.1 Brain Aging and cognition 
Aging leads to a function decline of many organs, including the brain. Age-related 
changes in the brain such as reduced insulin signaling, reduced neuronal 
glucose uptake, increased glucocorticoid levels, and increased intracellular 
calcium concentration may give rise to pathological brain aging. One of the 
hallmarks of brain aging is cognitive decline [1, 2]. Many factors could influence 
the age-related decline of cognitive function, including dysfunctions of circadian 
clock [3], and oxidative stress [4-9]. Growing evidence supports the concept that 
brain insulin and calcium may play an important role in the mechanisms behind 
memory decline in advanced age and Alzheimer’s disease (AD) [10-12]. At the 
cellular level, brain insulin deficiency and insulin resistance may be one of the 
fundamental changes associated with altered memory function during 
pathological aging [13-20]. Brain insulin signaling disruption has been closely 
associated with cognitive decline and AD [14, 21-25]. At the receptor level, the 
amount of insulin receptors and their functions are decreased in aging and AD 
animal models [26-28]. At the clinical level, studies suggest that memory 
improved in AD patients are due to changes in their insulin levels [29]. In aged 
animals, it has also been shown that intranasal delivery of insulin to the central 
nervous system (CNS) positively correlates with increased brain cognitive 
function [30]. The intranasal route of insulin administration increases insulin 
acutely in the brain without risk of peripheral hypoglycemia. Importantly, it 
significantly enhances the memory in both aged and AD patients [31-35]. 
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Although intranasal insulin enhances memory in AD patients, varying outcomes 
arise with its clinical setting usage. Men and women with AD respond differently 
to intranasal insulin dosage [36]. In addition, some clinical studies reported that 
patients carrying at least one copy of the Apolipoprotein E4 (the strongest 
genetic risk factor for late onset Alzheimer’s disease) did not benefit from 
intranasal insulin treatment [37]. Therefore, gender and ApoE status in AD 
patients increase outcome variability in intranasal insulin treatment. These 
varying outcomes highlighted the need to understand the underlying neuronal 
mechanism the effects of insulin on cognitive function with aging.  
 
1.2 Insulin  
Identifying the link between the pancreas and diabetes by Von Morning and 
Minkowski in 1890 opened the door for the discovery of insulin as a therapy. This 
life-sustaining hormone saved an enormous number of lives since its discovery. In 
the early twentieth century, Sharpey-Schafer hypothesized that pancreas secretes 
a hormone that controls glucose levels [38]. In 192, this hypothesis was confirmed 
and a novel protocol to purify insulin was developed. In 1922, insulin therapy was 
successful on a type 1 diabetic patient. Since the introduction of human insulin in 
1982 and insulin analogs in 1996, insulin therapy become the standard treatment 
options for diabetic patients [39, 40] by mimicking physiological insulin secretion in 
the body to regulate blood glucose levels. After almost 100 years of research, it is 
clear that Insulin is a natural peptide hormone secreted by the pancreatic β-cell in 
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response to elevated blood glucose concentration, and that it plays an 
indispensable role in maintaining blood glucose concentration and regulating 
metabolism [41]. In insulin therapy, to enhance the insulin’s effects and reduce 
the number of injection different routes of insulin delivery, as well as different 
insulin formulations were designed by combining insulin with zinc and/or basic 
proteins protamine [42]. 
 
1.3 Zinc 
Zinc is an essential ion involved in many physiological processes ranging from 
cell proliferation to neuronal function. Zinc plays a critical role in regulating insulin 
synthesis, storage, and secretion in the pancreatic beta cells [43-45]. Zinc 
combined with insulin and induces proinsulin hexamerization, also co-releases 
with insulin from the beta cells [46]. It is well documented that zinc, pancreatic 
beta cell, and diabetes have a strong cause and effect relationship. Zinc is highly 
abundant in the pancreatic islet and zinc deficiency has been associated with 
diabetes [47]. High levels of zinc can be toxic to the cells, specifically to the 
neurons [48, 49]. Zinc present in the brain with its highest concentration in the 
olfactory bulb, hippocampus, hypothalamus, and cortex. Increased zinc stimulates 
synaptic events via AMPA receptors and improves synaptic summation [50] and 
influences LTP induction and memory [51]. 
 
1.4 Insulin formulations and alternative routes for insulin administration 
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Insulin formulations (Table 1.1), also different routes of insulin delivery (e.g., 
nasal, pulmonary inhaled, intravenous insulin infusion, insulin pumps) were 
developed [52, 53]. Currently, insulin cannot take orally because it will break down 
in stomach before it regulates glucose levels. Earlier research has focused on 
understanding the molecular mechanism through which insulin regulates glucose 
to uncovered insulin’s potential effects on memory enhancement. Although insulin 
is effective and widely used, researchers continue to study the molecular 
mechanisms by which insulin regulates glucose uptake in fat, muscle, and 
neuronal cells to obtain even more benefits from this life-sustaining hormone.  
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Table 1.  Insulin Types by Brand Name, Generic Name, Onset, Peak, and 
Duration of Action. 
 
Type of Insulin Brand Name Generic Name Onset Peak Duration 
Rapid-Acting 
_NovoLog _Insulin aspart 
15 
minutes 
30 to 90 
minutes 
3 to 5 
hours 
_Apidra _Insulin glulisine 
15 
minutes 
30 to 90 
minutes 
3 to 5 
hours 
_Humalog _Insulin lispro 
15 
minutes 
30 to 90 
minutes 
3 to 5 
hours 
Short-Acting 
_Humulin R 
_Regular ( R) 30 to 60 minutes 
2 to 4 
hours 
5 to 8 
hours _Novolin R 
Intermediate-
Acting 
_Humulin N 
_NPH (N) 1 to 3 hours 8 hours 
12 to 16 
hours _Novolin N 
Long-Acting 
_Levemir _Insulin determir 1 hour Peakless 20 to 26 hours _Lantus _Insulin glargine 
Pre-mixed NPH 
(Intermediate-
acting) and 
regular (short-
acting) 
_Humulin 
70/30,  
_Novolin 
70/30 
_70% NPH 
and 30% 
regular 
30 to 60 
minutes Varies 
10 to 16 
hours 
_Humulin 
50/50 
_50% NPH 
and 30% 
regular 
30 to 60 
minutes Varies 
10 to 16 
hours 
Pre-mixed 
insulin lispro 
protamine 
suspension 
(Intermediate-
acting) and 
insulin lispro 
(rapid-acting) 
_Humalog 
Mix 75/25 
_75% insulin 
lispro 
protamine 
and 25% 
insulin lispro 
10 to 15 
minutes Varies 
10 to 16 
hours 
_Humalog 
Mix 50/50 
_50% insulin 
lispro 
protamine 
and 50% 
insulin lispro 
10 to 15 
minutes Varies 
10 to 16 
hours 
Pre-mixed 
insulin aspart 
protamine 
suspension 
(Intermediate-
acting) and 
insulin aspart 
(rapid-acting) 
_NovoLog 
Mix 70/30 
_70% insulin 
aspart 
protamine 
and 30% 
aspart 
5 to 15 
minutes Varies 
10 to 16 
hours 
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1.5 Insulin signaling in the periphery   
Insulin plays a vital role in maintaining blood glucose levels in the periphery. 
Insulin in the muscle and fat tissues promote glucose uptake. Insulin stimulates 
glucose storage, and inhibits glucose secretion in the liver [41, 54-61]. 
Insulin regulates glucose uptake in fat and muscle cells by inducing translocation 
of glucose transporters to the plasma membrane [62-68] by PI3K/AKT pathway 
[69]. Insulin also regulates glucose concentration via suppression of hepatic 
glucose production (HGP) [61, 70, 71]. Previous studies suggest that insulin 
regulates HGP by binding to the insulin receptor and activating serine/threonine 
kinases AKT [72, 73], which further inhibits Foxo1 phosphorylation [74-76]. 
Therefore, insulin prevents large alteration in blood glucose levels during the day 
by enhancing glucose metabolism in the cells and suppressing hepatic glucose 
production.  
 
 
8  
 
Figure 1.1 Mechanisms of Insulin Actions in the Periphery. 
 
In healthy individuals, blood glucose levels are tightly controlled by insulin, a 
natural hormone produced by the pancreatic beta cells in response to high blood 
glucose levels. In fat tissues, insulin increases triglyceride synthesis/ storage and 
decreases triglyceride breakdown. In the liver, insulin increases glycogen 
deposition and glucose use while decreasing glycogenolysis and 
gluconeogenesis. In muscle cells, insulin increases glucose uptake and protein 
synthesis while decreasing protein degradation. 
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Insulin promotes glucose uptake by cells through four major glucose transporter 
isoforms are widely distributed throughout the body. The glucose transporter 4 
(Glut-4) is highly expressed in fat and muscle cells [77]; Glut-1 and Glut-2 are 
expressed in the endothelial cells lining the blood vessels and liver, intestine, 
kidney, pancreatic cells; and Glut-3 is expressed in the neurons [78]. When 
insulin binds to the insulin receptors on the surface of target cells, it promotes 
translocation of glucose transporters to the plasma membrane, which moves 
glucose into the cell. Once glucose move inside the cell, it delivers energy to it. 
Altered insulin levels, insulin receptors and/ or glucose transporters all can lead 
to obesity, insulin resistance, and diabetes [79-83]. Although insulin is 
recognized as glucose regulating hormone, it is increasingly clear now that 
insulin also plays a critical role in the regulation of neuroplasticity, 
neuromodulation, neurotrophism, neuronal growth and survival [84-92]. 
Therefore, insulin is important not only for regulating sugar, but also for learning 
and memory. To initiate insulin signaling, insulin has to bind to the insulin 
receptor and activates the insulin receptor tyrosine kinase.  
Together with human insulin receptor characterizations, studies of insulin 
receptor tyrosine kinase activity have enhanced our understanding of the 
mechanisms of insulin action in various organs. Indeed, insulin acts on the fat, 
muscle, liver, and brain through the insulin receptor substrate pathways. 
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Figure 1.2 Insulin signaling pathways and translocation of glucose transporter 
(GLUT) to the plasma membrane by insulin.  
 
To initiate insulin signaling, insulin must bind to insulin receptors on the plasma 
membrane. Insulin receptors contain two α subunits outside the cell and two β 
subunits inside the cell. α subunits have an insulin binding site, and β subunits 
have a tyrosine kinase phosphorylation site. Once insulin binds to insulin 
receptors, it triggers autophosphorylation of β subunits of insulin receptors, which 
leads to phosphorylation of insulin receptor substrate (IRS), which further 
phosphorylates PI3K and AKT. Next, downstream signaling pathways promote 
translocation of glucose transporters (GLUT) to the plasma membrane, which 
brings glucose inside the cell modified from [93].  
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1.6 Insulin signaling in the brain 
While insulin plays an essential role in the brain, brain insulin itself is important for 
regulating insulin secretion from the pancreatic beta cells [94]. Important actions 
of insulin in the brain are now gradually becoming clear, even through the brain 
has been considered an insulin-independent organ for several decades. Insulin 
and insulin-like growth factor (IGF1-2) bind to insulin receptor and IGF-1R and 
initiate insulin signaling. Insulin receptor and IGF-1R co-express in the brain and 
share the intracellular signaling pathways; however, each of them has a unique 
function. This view has been further tested using neuron-specific insulin receptor 
and IGF-1R knockout mice. Deleting insulin receptors in the brain leads to mild 
obesity and insulin resistance without influencing brain size and development [95]. 
However, deleting IGF-1R affects brain size and development and contributes to 
behavior changes [96]. All the insulin receptor substrates (IRS1-4) present in the 
brain, and IRS2 play a vital role in the brain since their deletion results in impaired 
brain development [97, 98]. IRS mediate the phosphorylation of AKT/PI3K, which 
further activates several downstream signaling pathways [99]. Insulin downstream 
signaling promotes translocation of glucose transporters to the plasma 
membrane both in peripheral and brain tissues [62-68, 77, 100, 101]. Taken 
together, peripheral and brain insulin share similar signaling pathways.  
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Figure 1.3 Actions of insulin in the brain. 
 
The brain has been traditionally considered insulin-insensitive. However, now it is 
clear that normal brain functions depend on insulin, and insulin receptors are 
widely expressed in the brain. Insulin activates insulin signaling via binding insulin 
receptors and regulates various neuronal functions: it enhances learning and 
memory and regulates energy homeostasis, whole body metabolism, body 
temperature, mood, and appetite modified from [93].  
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This year we are celebrating the 96th anniversary of the discovery of insulin by 
Frederick Banting. Yet only over the past few years has interest increased in 
brain insulin’s role in cognition, food intake, body weight, and whole-body 
metabolism. Insulin in the brain has been detected at high levels in mouse 
embryos (E9) at early developmental stages and reduces with age [102]. Insulin 
receptors are located at brain synapses, and highly concentrated at the 
postsynaptic density [103]. Therefore, insulin may regulate synaptic function and 
excitatory synaptic transmission stability during neuronal development via insulin 
receptors. Furthermore, the insulin receptor substrate 53 (highly expressed in the 
postsynaptic density) also plays a role in regulating spine density in hippocampal 
cultured neurons [104]. 
 
 
1.7 Insulin receptors in the brain vs. in the periphery  
Insulin receptors belong to a tyrosine kinase family and activate through insulin 
binding [105]. The insulin receptor is a dimeric transmembrane protein encoded 
by a single gene, INSR, and alternative splicing of INSR gives rise to α  and 
β subunits. The insulin receptor is composed of two extracellular α subunits that 
bind to insulin and two intracellular β subunits with tyrosine kinase activity [106]. 
Insulin binds to α subunits of the insulin receptor, leading to autophosphorylation 
of β subunits and activating the receptor, which further phosphorylates and 
recruits different substrate (IRS) adaptor proteins [41, 107]. Insulin and insulin 
receptor signaling play an important role both in the periphery and the brain and 
 
14  
mediate many cell functions ranging from glucose metabolism to learning and 
memory. Furthermore, insulin receptors are expressed in almost all tissues in the 
body. However, researchers have found that the anti-insulin receptor that 
blocked the insulin receptor in the periphery had no effect on brain insulin 
receptors [108]. This study strongly supports that some structural and molecular 
differences exist between the peripheral and brain insulin receptors. Moreover, 
the difference between peripheral and brain insulin receptors is primarily due to 
alternative mRNA splicing of the exon-11.  
Brain insulin receptors lack exon-11, and therefore, brain insulin receptors have 
smaller subunits compared to peripheral insulin receptors [108-111]. Brain insulin 
receptors do not down-regulate in response to prolonged and/or a high 
concentration of insulin exposure [112, 113]. Brain insulin receptors reduce with 
aging and influence learning and memory, and learning improves insulin receptor 
functions [28]. These studies along with studies from the NIRKO mice model (a 
neuron-specific insulin receptor gene deletion [95] provide clear understanding of 
role of brain insulin receptor in brain function (food intake, metabolism, 
reproduction, cognition [114]. However, it is important to understand how insulin 
gets into the brain.  
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1.8 Insulin synthesis in the brain 
1.8.1 Peripheral source of insulin  
It is widely believed that insulin is synthesized and released mainly from the 
pancreatic beta cells in response to blood glucose levels.  Insulin is initially 
synthesized as preproinsulin, and removal of its amino terminal single peptide 
generates proinsulin. Excision of C peptide within the endoplasmic reticulum 
gives rise to α (21 amino acids) and β (30 amino acids) of insulin. C peptide is a 
biomarker of insulin secretion. Although various factors may influence insulin 
secretion, one key factor is blood glucose level.  When glucose concentration 
rises, glucose moves into the cell by a glucose transport. Then, glucose is 
metabolized to generate ATP, which blocks ATP- dependent K+ channels in the 
beta cell membrane, which results in the depolarization of the cell. Depolarization 
causes the Ca2+ ion channels to open, and Ca2+ ions to move in, which triggers 
vesicles containing insulin to move to the membrane fuse, and release the 
insulin by exocytosis.  
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Figure 1. 4 The mechanism of insulin secretion by the pancreatic beta cell. 
 
Increases in blood glucose levels trigger insulin release. Modified from Molecular 
biology of the cell (3rd ed.) by Alberts B, et al., 1994.  
1.8.2 Central source of insulin 
Previous studies show that insulin produced by the pancreas could enter the 
brain by crossing the blood brain barrier to maintain energy balance  [107, 115-
120]. Furthermore, insulin permeability changes during aging and in patients 
with diabetes and AD [121, 122]. Based on different experimental evidence, the 
brain also produces its own supply of insulin  [10]. In 1983, Dorn et al. confirmed 
the hypothesis that part of the brain insulin is produced in the central nervous 
system (CNS). Results from the study of human cadaver brains demonstrated 
that insulin and C-peptide were present in most nerve cells [123]. Further, C-
peptide and insulin receptors in the brain decreased with aging [124]. Unlike 
mammals, in drosophila and C.elegans, neurons are the primary cells to 
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produce insulin  [99]. Together with animal studies and observations from 
hippocampal cultured neurons studies, it is clear that insulin can be synthesized 
locally in the brain and released from the neurons in response to depolarization 
[125, 126]. While brain insulin and insulin receptor signaling undergo changes 
with aging, insulin resistance may contribute to pathological brain aging [127-
133].  
Insulin also is valuable for treating a wide variety of non-diabetic diseases, such 
as schizophrenia, anxiety, nervousness, cancer, and cognitive function. While 
insulin in the brain enhances learning and memory, insulin resistance is linked 
to Alzheimer’s disease and other neurodegenerative disorders [134-136]. 
Currently, increasing insulin signaling in the brain is one of the best treatment 
options to improve memory in aged and AD populations [137]. 
 
1.9 Metabolism and the brain  
The brain is a complex organ and needs lots of energy to run properly [138]. 
Glucose is the main substrate that satisfies brain high-energy demands. The 
brain (rich with neurons) weighs only 2% of body weight, but neurons use 25 
percent of all the glucose energy in the body while its energy store capacity is 
small. Hence, the brain requires a constant glucose supply from the blood, and 
glucose is transported into the brain via the glucose transporters through the 
blood brain barrier. Although the brain is an energy-intensive organ, it has 
traditionally been considered insulin-insensitive. However, recently this view has 
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been challenged, and now it is clear that normal brain function depends on 
insulin. Moreover, brain functions such as learning and memory are positively 
correlated with effective glucose metabolism in the brain. Dysregulation of brain 
glucose metabolism can lead to loss of energy for brain functions, which further 
influences the neurotransmitters, neuronal communication, and cognitive 
function. Therefore, the traditional role of Insulin in the brain is regulating glucose 
metabolism and enhancing neuronal survival. It is also known that insulin and 
insulin receptors in the brain reduce with aging [124]. Additionally, the link 
between metabolic disturbances and neurodegenerative diseases have been 
well documented. Researchers have suggested that Alzheimer’s disease is 
positively correlated with obesity and diabetes  [16, 139-145]. Previous studies 
suggest that type 2 diabetes increases the risk of developing AD [146-149]. Also, 
some studies suggest that AD is a brain- specific form of diabetes (type 3 
diabetes) [150-155]. Furthermore, clinical studies suggest that AD patients 
present abnormal brain glucose metabolism  [26, 156]. Normal brain glucose 
metabolism is vital for brain function and controlled by brain insulin/insulin 
receptor signaling pathways [157]. 
Insulin in the brain is the key to many neurological disorders. In fact, brain insulin 
regulates both periphery and central glucose metabolism, learning, and memory 
[87, 107, 158, 159]. Insulin exerts its effects though insulin receptors, which are 
widely distributed in various regions of the brain  [107, 160-162]. More 
specifically, insulin receptors are highly expressed in the hippocampus  [107, 
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163], a brain region that is critical in synaptic plasticity, learning, memory, and 
cognition. Brain insulin and insulin receptor levels decrease with aging and AD, 
which is linked to age-related memory impairment [152, 164-166]. Insulin 
receptors are also expressed in the hypothalamus, the widely studied region of 
insulin action in the brain. Insulin circulates at the level proportionate to body fat 
mass, inhibits food intake through its actions on the hypothalamic neurons [167, 
168], and regulates glucose metabolism [169] and energy expenditure [170] both 
in the periphery and the brain [171]. The highest concentration of insulin and 
insulin receptors are detected in the olfactory bulb [172, 173], and insulin 
regulates olfactory functions, which are important for food intake and appetite 
[174]. Insulin receptors are also present in the cerebral cortex and cerebellum 
[28] and plays an important role for neuronal survival [158]. Furthermore, Kahn et 
al created neuron-specific insulin receptor knockout mice (NIRKO) to study 
insulin actions in the brain. The study results suggest that depletion of insulin 
receptors in neurons lead to obesity and dysregulation of a reproduction 
hormone [95]. Insulin has diverse effects in the brain. Insulin may promote better 
nerve cell communication, but the disruption of brain insulin signaling may lead 
to metabolic dysregulation and cognitive impairment [87, 134, 175]. Insulin has 
also been viewed as the potential missing link between memory and intracellular 
Ca2+ dysregulation with aging. Insulin regulation of glucose homeostasis is an 
important modulator of neuronal plasticity. Also, maintenance of intracellular 
Ca2+ homeostasis is vital for normal synaptic plasticity as well as cell excitability. 
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1.10 Intracellular calcium levels  
Calcium (Ca2+) is an essential ion that rules many aspects of cellular life, 
including cellular excitability, exocytosis, apoptosis, toxicity, and transcription, 
and mediates many cell functions, including muscle contraction, chemical sense, 
cell proliferation, fertilization, immune response, learning and memory. For this 
reason, intracellular Ca2+ levels are precisely regulated in young healthy 
individuals. However, failure of this regulation occurs with aging and AD. The first 
proposal of a “Ca2+ hypothesis of brain aging” by Khachaturian in 1984 provides 
a simple cellular mechanism that alters Ca2+ homeostasis underlying many age-
related changes. After two more decades of studies, the relationship between 
dysregulation of intracellular Ca2+ and pathological brain aging has become 
clear and is now the key therapeutic target to treat many neurodegenerative 
diseases. 
Thanks to the excellent work of Sydney Ringer, who in 1883 discovered the 
importance of Ca2+ signaling in the survival of fish, heart, and muscle 
contraction. After 50 years, in the early 1940s, Lewis Victor Heilbrun confirmed 
the theory that Ca2+ is a universal intracellular messenger able to regulate all 
cellular reactions and that Ca2+ also involves neurotransmitter release into nerve 
terminals  [176, 177]. After several decades of research, it is clear that in the 
brain, Ca2+ plays a critical role for synaptic activity, neuronal development, 
neuronal survival, and cognition [178-180]. Discovery of patch clamping and 
Ca2+ imaging techniques advanced our understanding of pathology associated 
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with dysfunctions of Ca2+ signaling cascades [181]. At rest, intracellular Ca2+ 
concentration is very low (~100 nM free) and extracellular Ca2+ concentration (~ 
2 mM) is high, about a 20,000–fold concentration gradient. Intracellular [Ca2+] is 
maintained within a specific limit by the different Ca2+ handling mechanisms 
[182]. However, brain aging contributes to the loss of intracellular Ca2+ 
homeostasis  [183, 184]. In healthy individuals, intracellular Ca2+ homeostasis is 
tightly regulated and plays a vital role in neuronal survival and function. In 
contrast, intracellular Ca2+ levels increase with aging, which contributes to 
memory decline and other neurodegenerative disorders such as AD [180, 185, 
186]. Specifically, an age-related increase in hippocampus Ca2+ levels has been 
much investigated during the last several decades because Ca2+-dependent 
after hyperpolarization is larger (AHP) in aged animals and links to cognitive 
impairment with aging and AD [180, 182, 185-192]. In addition, high intracellular 
Ca2+ levels and larger Ca2+ dependent AHP are seen in the hippocampus of 
diabetic rats [193, 194].  
It appears that the increase in hippocampal intracellular Ca2+ levels are mainly 
mediated through voltage gated Ca2+ channels and N-methyl-D- aspartate 
(NMDA) receptors on the plasma membrane, and intracellular Ca2+ release via 
ryanodine receptors on the endoplasmic reticulum [195].  
1.10.1 Voltage-gated Ca2+ channels 
Voltage-gated Ca2+ channels (VGCCs) are found in the membrane of neurons, 
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muscles, glial cells (excitable and non-excitable cells), and are permeable to 
Ca2+ ions [196]. VGCCs are voltage-sensitive and mediate the fastest Ca2+ 
influx in response to membrane depolarization, thus, changing intracellular Ca2+ 
levels greatly within milliseconds [197-201]. As a result, Ca2+ enters the cell 
through voltage-gated Ca2+ channels and serves as intracellular second 
messengers to control a wide variety of cell functions. In cardiac, smooth, and 
skeletal muscles, activation of VGCCs mediates contraction by increasing 
intracellular Ca2+ levels and by further activating ryanodine dependent Ca2+-
induced Ca2+-release in the sarcoplasmic reticulum [202-206]. In the endocrine 
cells, VGCCs activation influences the hormone secretion [207]. In the neurons, 
Ca2+–mediated process via VGCCs include synaptic transmission, 
neurotransmitter release, and gene transcription; it also activates calmodulin-
dependent protein kinase ll (CaMKll) and protein kinase C (PKC) which are 
important for neuronal survival, learning and memory [198, 208-217]. While Ca2+ 
channels serve as a key pathway for entry of Ca2+ into the neuron and initiate 
many physiological events, inappropriate expression or dysfunction of VGCCs 
can result is pathophysiological changes leading to neuronal Ca2+ dysregulation 
and toxicity in the brain, which have been linked to neurodegenerative diseases 
[218-221]. Furthermore, VGCCs density increases with aging, and this 
contributes to cognitive decline with aging and AD [184, 222-224]. Therefore, 
voltage-gated Ca2+ channels are important therapeutic targets for age-related 
cognitive decline and other conditions.  
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1.10.2 Structure and classification of voltage-gated Ca2+ channels 
The five-polypeptide subunit that forms voltage-gated Ca2+ channels is a central 
pore-forming α1 subunit, dimer of α2 and δ subunits and intracellular β subunit, 
and transmembrane γ  subunit. There are ten Cavα1 subunits that share four 
homologous domains, each with six membrane-spain helices (S1-S6). S4 
(Positively charged and hydrophobic) is the key controller for voltage-dependent 
activation [197, 198, 208, 225-227] and P loop motif  (negatively charged) is 
located between S5 and S6. Together they form a pore that is permeable to 
Ca2+ and barium  [197, 228].  
 
Figure 1.5 Voltage-gated Ca2+ channels structure. 
 
High voltage activated (HVA) channels (P, Q, N, L, R-type) contain Caα1, Caβ, 
Caγ, and Caα2δ subunits. Low voltage activated channels (T-type) contain 
Caα1subunit modified from [220]. 
 
 
24  
The Caα1 subunit has three main families (Cav1, Cav2, Cav3) [226, 229]. The 
Cav1 family includes four members (Cav1.1, Cav1.2, Cav1.3, Cav1.4) and all 
four members encode neuronal L-type Ca2+ channels and Cav1.1 encodes 
skeletal muscle Ca2+ channels [230-233]. Further, Cav1.1 knockout mice cannot 
contract their diaphragms and die at birth [234]. Mice that lack Cav1.2 die in 
utero because the heart muscle cannot contract [235]. Cav1.2 is also important 
for neuronal function and mutations in this subunit links to bipolar disorder, 
Schizophrenia, and depression [236-239]. Cav1.3 null mice are deaf due to loss 
of Ca2+ current [240] and loss of normal auditory brain stem development [241]. 
Mice deficient in Cav1.4 are blind due to loss of normal function in the outer 
retina [242, 243]. 
The Cav2 family has three members (Cav2.1, Cav2.2, Cav2.2) and gives rise to 
P/Q-type [244], N-type, and R-type Ca2+ channels [233]. The Cav3 family has 
three members (Cav3.1, Cav3.2, Cav3.3) that encode T-type channels [245]. 
Mice with a lack of Cav2.1, Cav3.1, and Cav3.2 display a range of dysfunctions 
(seizures, slow heart rate, compromised coronary, epilepsies) [246-250]. 
The Cavβ subunit has four members (Cavβ1- Cavβ4) and links to Cavα1 domain 
l-ll [251, 252]. The Cavα2δ subunit has four different members (Cavα2δ1− 
Cavα2δ4) and is anchored to extracellular plasma membrane via 
glycophosphatidylinositol (GPI) [253-255]. Earlier studies suggest that the 
Cavα2δ subunit plays an important role in regulating synaptic targeting and 
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release probability of voltage-gated Ca2+ channels in neurons [256, 257]. 
Table 2. Types of voltage gated Ca2+ channels (VGCCs) activation and 
inactivation profiles modified from [258]. 
Native current α1-Subunit subtypes 
Activation 
profile 
Inactivation 
profile 
Ca2+-
dependent 
inactivation 
P/Q-type α1A (CaV2.1) High voltage Moderate/slow Yes/no 
N-type α1B (CaV2.2) High voltage Fast Yes/no 
L-type 
α1C (CaV1.2) 
High voltage Moderate/slow Yes 
α1D (CaV1.3) 
α1F (CaV1.4) 
α1S (CaV1.1) 
R-type α1E (CaV2.3) High voltage Fast/moderate No 
T-type 
α1G (CaV3.1) 
Low voltage Very fast No α1H (CaV3.2) 
α1I (CaV3.3) 
 
 
 
There are several members of the VGCCs in the brain due to different genes that 
encode ten α1 subunits of Ca2+ channel, including L-type, N-type, P/Q-type, R-
type, and T-type channels [214, 259]. Based on physiological and 
pharmacological properties, they are categorized as high voltage (HVA) and low 
voltage (LVA). HVA channels (L- type, P/Q-type, N-type) formed through a 
combination of Cavα1, Cavβ, and Cavα2δ subunits activate in response to strong 
and large depolarization. On the other hand, Low voltage-activated (T-type) 
channels only contain the Cavα1 subunit and open in response to weak 
depolarization [226, 260-263]. The R-type is intermediate voltage activated 
channels. In neurons, both HVA and LVA channels can control neuronal firing 
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properties [264-268]. 
1.10.3 Voltage-gated Ca2+ channels activation and inactivation 
Activation of voltage-gated Ca2+ channels results in Ca2+ influx and mediates 
neurotransmitter release, neuronal firing, hormone secretion, muscle contraction, 
and gene expression. However, prolonged activation of Ca2+ channels 
contributes to elevation of intracellular Ca2+ levels, which is cytotoxic [221]. 
Therefore, there are two types of Ca2+ channel inactivation, voltage- and/or 
Ca2+-dependent inactivation, to limit intracellular Ca2+ overload. All voltage-
gated Ca2+ channels can be inactivated by voltage-dependent manner [269]. 
The underlying mechanism responsible for voltage-dependent Ca2+ channel 
inactivation is different from voltage-gated K+ and Na+ channels (“ball and chain” 
and “Hinged-lid”) mechanisms [270].  Many studies suggest that prolonged 
depolarization triggers structural changes in four S6 of the α1 subunits, and 
further exposes docking site for the domain l-ll linker. Thus, it modulates 
inactivation of voltage-gated Ca2+ channels  [269, 271-273]. Other subunits of 
Ca2+ channels also influence the kinetics and rate of inactivation.  
Voltage-gated Ca2+ channels inactivate not only in response to voltage, but also 
to the influx of Ca2+ [274]. Ca2+-dependent inactivation becomes important 
when studying the effects of drugs on Ca2+ channel currents. A rise in 
intracellular Ca2+ triggers binding of Ca2+ to the channel and initiates 
inactivation [275] and Calmodulin plays a vital role in Ca2+-dependent 
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inactivation [276]. Therefore, barium was used as a charge carrier when 
obtaining Ca2+ channel currents while studying insulin effects on VGCCs. 
1.10.4 Ryanodine receptors 
Ryanodine receptors (RyRs), intracellular Ca2+ release channels, are located in 
the endoplasmic (ER) reticulum membrane [136, 277], and mediate rapid 
intracellular Ca2+ release into the cytosol, which allows the amplification of 
intracellular Ca2+ concentration. RyRs are widely expressed in almost all tissues 
(muscle, myocardium, and neurons) and are involved in a variety of key Ca2+ 
signaling events [278], ranging from excitation-contraction coupling in muscle 
cells to learning and memory in nerve cells. There are three major RyRs isoforms 
(RyR1-3) and they are named after plant alkaloid ryanodine [279]. Ryanodine is a 
natural agonist at low concentration, which allows efflux of Ca2+ from ER and 
increases intracellular Ca2+ levels. At high concentrations (~20 uM), Ryanodine 
is an antagonist, which inhibits the Ca2+ flow out of the ER.  
RyRs are the largest ion channels and the highest-conductance intracellular 
Ca2+ channel, with a molecular mass that is  greater than megadalton [280]. 
RyRs are regulated by the Ca2+ ion and VGCCs [281]. Ca2+ influx through 
voltage-gated Ca2+ channels triggers second messenger signals that open the 
RyRs channels and give rise to large Ca2+ release from internal Ca2+ stores 
(endoplasmic reticulum) [282, 283]. Thus, Ca2+ activation of the RyRs on the 
endoplasmic reticulum amplifies the intracellular [Ca2+] through Ca2+-induce 
Ca2+-release (CICR) process [284]. Additionally, various ions, small molecules, 
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and proteins may also regulate the RyRs function, including protein kinase A 
(PKA), FK506 binding proteins, and calmodulin (CaM) [285-287]. In skeletal and 
cardiac muscle, RyR1 and RyR2 play a critical role in excitation and contraction 
coupling [288, 289]. High intracellular Ca2+ concentration induces muscle 
contraction and Ca2+ ATPase dependent Ca2+ uptake by sarcoplasmic 
reticulum results in relaxation [281, 290]. In neurons, RyRs are crucial for signal 
transduction and influence hormone secretion, synaptic plasticity, and learning 
[291-293]. 
 
Figure 1.6 Ryanodine receptors and cognitive function with aging 
 
Ryanodine receptors (RYRs) on the endoplasmic reticulum (ER) undergo 
functional changes with aging. Furthermore, the RYRs mediated increase in 
Ca2+-induced Ca2+-release (CICR) is one of the major sources of Ca2+ 
dysregulation with aging. Moreover, amplified CICR influences the size of AHP 
and cognitive function.  As a result, dysfunction of RYRs leads to an increase in 
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intracellular Ca2+ via CICR, which further contributes to larger AHP, Ca2+ 
dysregulation, and memory decline.  
 
 
1.10.5 Ryanodine receptor isoforms and expression 
Ryanodine receptor isoforms are RyR1, RyR2, and RyR3 and are expressed in 
various tissues. RyR1 is the most intensely studied type and its main function is 
to trigger Ca2+ efflux from the sarcoplasmic reticulum membrane of skeletal 
muscle. RyR1 is highly expressed in the skeletal muscle [294, 295]. Also, it is 
widely distributed in cardiac muscle, smooth muscle, stomach, kidney, thymus, 
cerebellum, purkinje cells, adrenal glands, ovaries, testis, and B-lymphocytes at 
low levels [294, 296-299]. Dysfunction of the RyR1 gene is associated with life-
threatening muscle diseases such as malignant hyperthermia [300] and 
multiminicore disease [301]. 
RyR2 is dominantly expressed in the cardiac muscles [277]. Different 
concentrations of RyR2 are also detected in purkinje cells of the cerebellum, 
cerebral cortex, stomach, kidney, adrenal glands, ovaries, thymus, and lungs 
[302-305]. Mutation in the RyR2 gene may cause arrhythmogenic right 
ventricular dysplasia type 2 and Ventricular arrhythmias by changing Ca2+ 
homeostasis [306-308].  
RyR3 is present in the brain and mainly found in the hypothalamus, corpus 
striatum, and hippocampal neurons [296, 304, 309]. Different studies suggest 
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that inappropriate expression or dysfunction of RyR3 links to Alzheimer’s disease 
[136, 186]. 
 
1.10.6 Structure of ryanodine receptors 
All three isoforms (RyR1, RyR2, RyR3) share similar structure. The structure of 
RyR1 (Skeletal muscle ryanodine receptors) is widely studied and it includes four 
identical subunits and is divided into two regions: a transmembrane (TM) region 
and a cytoplasmic (CY) region [294, 295]. The CY region plays a critical role in 
regulating RyR1 channel gating properties via interacting with intracellular 
messengers. Dysregulation of the CY region of RyR1changes its gating and links 
to many diseases [310].  
RyR2 is dominantly expressed in the heart and brain and is activated by Ca2+ 
influx through plasma voltage-gated Ca2+ channels in response to 
depolarization. Peng et al. used electron microscopy to map the structure of open 
and closed states of RyR2 from porcine hearts. The results suggest that RyR2 
has different cytoplasmic domain compare to RyR1 due to rotation of the central 
domain, which influence the RyR2 channel gating [311].  
  
1.11 Hippocampus  
Hippocampus is critical for learning and memory [312] and is highly vulnerable 
to damage and loss during aging and AD [111, 191, 313-315]. The 
hippocampus, located in the medial temporal lobe, belongs to the limbic family, 
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one on each side of the brain. The human hippocampus has a curved shape 
resembling a seahorse; it appears as a ‘C’ shape in hippocampal cultured 
neurons. In addition to the hippocampus, the cerebellum, amygdala, and other 
systems are also involved in learning and memory. 
The hippocampus is responsible for the formation and consolidation of short-
term memory and long-term memory, as well as spatial navigation. The H.M 
study is the starting point for understanding the importance of the hippocampus 
in memory. H.M is a famous patient whose case provided an understanding of 
how our brain works. After the neurosurgeon removed H.M’s hippocampus, 
patient was unable to form new memories, and, as a result, he forgot daily 
events as fast as they occurred [316]. The H.M case study continued for five 
decades until his death, and the study results shed light on the relationship 
between cognitive and neuronal organization of memory [317]. Since H.M 
became amnesic after bilateral hippocampus lesion, the removal of 
hippocampus is responsible for his memory impairment; moreover, magnetic 
resonance imaging study further confirmed that lesion of the hippocampus can 
result in global and enduring amnesia [318]. This study, along with cumulative 
animal studies, made it clear that the hippocampus plays a critical role in the 
formation of immediate memory, long-term memory, and memory retention [319]. 
In addition, earlier studies suggest that the hippocampus volume decreased with 
aging [320]. Furthermore, in neurodegenerative diseases such as Alzheimer’s 
disease, the hippocampus is one of the first brain regions to become damaged. 
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Also, an increase in hippocampal neurogenesis is one of the hallmarks of early 
AD [321, 322].  
On the other hand, in healthy individuals, high levels of insulin receptors have 
been seen in CA1, a hippocampal region that is important in learning and 
memory [159, 323]. The interruption of insulin production and insulin receptor 
activity may cause cognitive decline [28]. Also, neuron loss in the CA1 region of 
the hippocampus differentiates the healthy individual from AD patients [313, 324-
326]. Therefore, losing and/or damaging the hippocampal neurons causes 
significant cognitive problems. 
  
1.12 Insulin actions on neurons 
Insulin has wide raging effects in neurons of various brain regions, including 
regulating neuronal activity and synaptic function. Insulin and insulin receptors 
are present in the fetal central and peripheral nervous system, where it 
promotes axonal growth and brain development in the hippocampal cultured 
neurons [327]. Insulin can be produced and released from the hippocampal 
cultured neurons in response to depolarization [125, 126]. Insulin inhibits 
norepinephrine uptake by the hippocampal cultured neurons [328]. In the 
hypothalamus, insulin reduces the activity of POMC, AgRP, and steroidogenic 
factor 1 (SF-1) neurons through KATP channel activation [329, 330]. In the 
hippocampus, insulin increases insertion of NMDA receptors into the cell 
membrane [89] via tyrosine phosphorylation of NR2A and NR2B subunits [85]. 
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Thus, insulin may promote long-term potentiation, which is important for learning 
and memory. Insulin-dependent internalization of the AMPA receptor [88, 331, 
332] is important for long-term depression, which is another important 
mechanism for consolidation of navigational memory in the hippocampus. Insulin 
also regulates inhibitory synapse by increasing cell surface GABAA receptor 
expression [91, 92, 333]. In addition, insulin enhances synaptic plasticity by 
increasing the expression of dendritic postsynaptic density scaffolding protein 
(PSD-95), which is important for the formation of the postsynaptic junction [334] 
and Ca2+ homeostasis in hippocampal neurons (Maimaiti et al., 2017). Insulin 
stimulates the translocation of glucose transporter-4 (Glut-4) to hippocampal 
plasma membranes [100]. Glut-4 is important for glucose uptake and utilization 
in the brain. As a result, insulin regulates neuronal metabolism and energy 
needed for learning and memory via Glut-4. In addition, insulin also regulates 
visual system function by controlling synapse density [84]. Insulin modulates L-
type Ca2+ current and intracellular Ca2+ levels in rod photoreceptors [335].  
 
1.13 Thesis significance 
Hippocampus-dependent memory loss is one of the hallmarks of brain aging and 
Alzheimer’s disease (AD). This growing epidemic includes an estimated 5.3 
million people in the United States, with the economic burden on healthcare 
estimated at 259 billion dollars (http://www.alz.org/facts/). Most importantly, the 
day-to-day lives of those affected by AD and their families must be considered 
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as we investigate new therapeutic targets and new approaches for the 
treatment of this devastating disease. Indeed, AD therapeutic options are very 
limited in their ability to improve the lives of those impacted by this disease. 
Therefore, innovative and effective therapeutic strategies are necessary to 
address the needs of this patient population.  
In recent years, the study of insulin as a cognitive enhancer has gained 
momentum. Insulin and its receptors have been detected in the hippocampus, 
one of the major brain regions that is damaged and/or lost in Alzheimer’s 
disease [155, 336]. In addition, insulin regulates energy for proper brain function 
and survival [158], and insulin signaling has been shown to be deficient in 
postmortem brain tissue of AD patients [337, 338]. Thus, increasing insulin 
signaling in the brain appears to be a valid therapeutic target for improving 
cognitive function in aging and/or AD. Earlier clinical trials have shown that 
intranasal insulin treatment significantly improves memory in AD patients [31-
35] .Therefore, based on these clinical studies as well as animal studies, 
intranasal insulin administration appears to be one of the best methods to treat 
cognitive decline due to its minimal effect on systemic glucose levels and noted 
improvements in memory processes. However, there have been only a few 
studies focusing on identifying the neuronal molecular mechanisms underlying 
these effects. My dissertation is designed to identify the potential mechanisms 
responsible for insulin-mediated memory improvement as those seen in human 
and animal studies. Specifically, I focus on identifying whether insulin can offset 
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cognitive decline with aging through a mechanism dependent on reestablishing 
Ca2+ homeostasis.  
Intracellular Ca2+ signaling may be a key neuronal molecular regulator of 
hippocampal-dependent memory. Intracellular Ca2+ levels increase associates 
with memory decline in aging and AD [156, 314, 339, 340]. Thus, we examined 
the relationship between insulin, memory and intracellular Ca2+ levels to better 
understand the mechanism(s) underlying insulin action on hippocampal 
neurons. This information will enable to us to better understand how insulin 
therapy may affect patients and may also shine light on the underlying neuronal 
mechanisms. 
The following manuscript has been published in the Journals of Gerontology: 
Series A: J Gerontology A Bio Sci Med Sci. 2016 Jan;71(1):30-9. Epub 2015 
Feb 6. As an initial step, we explored the role of intranasal insulin in improving 
hippocampal-dependent memory in experimental aged animals. Additionally, we 
delineated insulin’s effects on Ca2+-dependent after hyperpolarization in the 
CA1 region of the dorsal hippocampus using hippocampal slices recordings in 
young and aged rats. Because brain aging is the greatest risk factor for AD, 
studies into how insulin may alter biomarkers of brain aging could improve 
current therapeutic strategies for memory loss with aging and AD.  
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Chapter 2 Intranasal insulin improves age-related cognitive deficits and 
reverses electrophysiological correlates of brain aging 
Authors: Shaniya Maimaiti, Katie L Anderson, Chris DeMoll, Lawrence L Brewer, Ben 
Rauh, Chris J Gant, Erick Blalock, Nada M. Porter, Olivier Thibault 
 
Synopsis 
Peripheral insulin resistance is a key component of metabolic syndrome 
associated with obesity, dyslipidemia, hypertension, and Type 2 diabetes. While 
the impact of insulin resistance is well recognized in the periphery, it is also 
becoming apparent in the brain. Recent studies suggest that insulin resistance 
may be a factor in brain aging and Alzheimer’s disease (AD) whereby intranasal 
insulin therapy, which delivers insulin to the brain, improves cognition and 
memory in AD patients. Here, we tested a clinically-relevant delivery method to 
determine the impact of two forms of insulin, short-acting insulin lispro 
(Humalog®) or long-acting insulin detemir (Levemir®), on cognitive functions in 
aged F344 rats. We also explored insulin effects on the Ca2+-dependent 
hippocampal afterhyperpolarization (AHP), a well-characterized 
neurophysiological marker of aging which is increased in the aged, memory 
impaired animal. Low-dose intranasal insulin improved memory recall in aged 
animals such that their performance was similar to that seen in younger animals. 
Further, because ex vivo insulin also reduced the AHP, our results suggest that 
the AHP may be a novel cellular target of insulin in the brain, and improved 
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cognitive performance following intranasal insulin therapy may be the result of 
insulin actions on the AHP. 
2.1 Introduction 
Results from preclinical settings argue that peripheral insulin resistance, a 
component of type 2 diabetes and/ or the metabolic syndrome, may have a 
negative impact on cognitive function. Emerging studies report that in diabetic 
models, insulin responses are attenuated in the brain, possibly indicating the 
presence of insulin resistance in this tissue. Clinical and preclinical studies show 
that insulin and insulin-like growth factor-1 (IGF-1) receptors, their message and 
their function, are often reduced in the hippocampus during normal and 
pathological aging [27, 111, 124, 150, 341]. Similarly, in animal models of aging 
and Alzheimer’s disease (AD), brain insulin receptor signaling is reduced, often in 
the presence of peripheral metabolic dysregulation [28, 342-348]. Importantly, 
several studies provide evidence that brain insulin therapy can greatly reduce 
cognitive decline with age and/ or AD, and even improve memory in young adults  
[reviewed in 33].  
In recent studies examining the effects of insulin on cognition, insulin has been 
administered via the intranasal route to bypass the blood brain barrier. Notable, 
Born and colleagues have shown that intranasal insulin is capable of entering the 
human brain rapidly [349]. However, the underlying mechanism(s) leading to 
cognitive improvement are not yet clear. Potential molecular/ cellular targets 
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affected by insulin in the brain and capable of offsetting cognitive decline include 
changes in neuronal firing [350], Ca2+-dependent K+ channels [351], GABA 
currents [352] and tau and Aβ metabolism [353-355]. Insulin also alters synaptic 
structures [356, 357], modifies synaptic plasticity [88, 358, 359] and increases 
delivery of NMDA receptors to the plasma membrane [89]. Similar effects have 
been observed in response to IGF-1 replacement, showing increased AMPA-
mediated excitatory postsynaptic potentials [360, 361], and increased NMDA 
receptor trafficking [362], effects that appear capable of offsetting age-dependent 
cognitive decline [363]. Further, MRI data in men and women has provided 
evidence that intranasal insulin can have an impact on brain blood flow [364], 
and on whole-body insulin sensitivity via regulation of hypothalamic activity [365, 
366]. Whether this later effect is purely mediated by central insulin effects or 
reflects permeation of small insulin amounts into the bloodstream is currently 
being investigated [367-369].  
Another important candidate mechanism that may underlie the effects of 
intranasal insulin pertains to Ca2+ homeostasis. Ca2+ dysregulation is prominent 
in models of diabetes [370]. In the dorsal root ganglion and the hippocampus of 
animals with STZ-induced diabetes [193, 371], broader Ca2+ action potentials, 
larger Ca2+-dependent afterhyperpolarizations (AHPs), and aberrant intracellular 
Ca2+ release are seen [193, 372, 373]. Impaired memory and long-term 
potentiation maintenance is also present [374]. Clinical data also supports a role 
for Ca2+ dysregulation in peripheral insulin resistance as evidenced by the 
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presence of abnormal and sustained adipocyte Ca2+ elevations in 
hyperinsulinemic, obese subjects [375]. Similar evidence for an increase in Ca2+ 
levels in skin fibroblasts from Type 2 diabetics has also been reported [376]. In 
recent work, we have shown that the Ca2+-dependent AHP, which increases in 
amplitude and duration with aging [377-379], is sensitive to insulin (ex vivo), and 
that this sensitivity is reduced by a high fat diet [380]. 
While some studies in humans demonstrate the efficacy of intranasal insulin as a 
cognitive enhancer, studies in animal models are required to understand the 
potential mechanisms underlying the beneficial effects of intranasal insulin. 
However, only one prior study has measured the impact of intranasal insulin on 
brain function in the awake animal, focusing on olfactory discrimination in the 
young mouse [381]. Because the greatest risk factor for AD is aging, research 
into how central nervous system insulin signaling affects brain aging may 
improve understanding of the biological conditions. Further, because of the 
sustained growth in the aging population, implementing strategies to reduce the 
impact of brain aging will likely benefit the aging population, and by extension, 
may reduce the incidence of age-related neurodegenerative diseases that share 
cellular mechanisms with brain aging (e.g., AD). 
We, therefore, assessed learning and memory performance in aged rats in 
response to two different insulin formulations (short-acting insulin Humalog® and 
long-acting insulin Levemir®), and quantified Ca2+ homeostasis. Insulin is 
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available primarily in shorter- and longer-acting forms, and intranasal longer-
acting insulin formulations (e.g., Levemir®) may potentially be superior to 
shorter-acting ones (e.g., Humalog®) especially in APOE-ε4 carriers [382]. In 
addition, because insulin is often formulated with zinc, to more specifically 
address the impact of insulin, we studied a zinc-free insulin formulation (Apidra® 
), as well as zinc alone on the AHP. Overall, our goals were to test whether 
intranasal insulin could reduce cognitive decline in aged animals, as well as 
redress the accompanying neuronal Ca2+ dysregulation seen in the 
hippocampus of aged animals.  
 
2.2 Methods 
Animals: Young male F344 (3 months old), aged male F344 (21 months old), 
and young male Sprague-Dawley rats (2-6 months old) were used for this study. 
Young F344 animals were not treated with insulin, and were used to help gauge 
the impact of intranasal insulin on memory function in aged F344. All animals 
were fed an 18% protein rodent diet (Harlan Teklad, diet #2018; Madison, WI). 
In vivo insulin delivery and doses: Levemir® doses were approximately 
0.0715, 0.143, or 0.286 IU/day/rat delivered in two 5 uL applications applied to 
the tip of the right naris using a P10 Eppendorf pipette (see supplemental figure 
1) [adapted from 383]. Humalog® dose was chosen to deliver 0.0715 IU/day/rat 
for behavioral characterization. An intranasal 0.286 IU/rat dose was also 
administered once to aged animals (n = 3) to monitor the impact on peripheral 
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glucose (supplemental Table 1). Each application was separated by 1 min, 
during which the animal was held supine and immobile in a DecapiCone® 
(Braintree Scientific Inc., Braintree, MA). Each animal was acclimated to this 
procedure for 4 days prior to initiation of the Morris water maze protocol. All 
animal groups were exposed to the DecapiCone® for the same duration, and no 
signs of stress from the bagging procedure were noted. The insulin doses were 
chosen to approximate several clinically-relevant doses used in past studies 
ranging from 10 IU/day to 40 IU/day and were adjusted by brain weights. 
Assuming a 70 year old human brain weighs 1360 g [384], 10, 20 and 40 IU/day 
are equivalent to 0.0074, 0.0147, and 0.0294 IU/day/g of brain, respectively. 
Assuming a 21 month old F344 brain weighs 2.06 g [385], our equivalent doses 
were 0.035, 0.069 and 0.138 IU/day/g of brain. It should be noted that these 
values may underestimate final insulin concentration given the greater olfactory 
epithelium surface in the nasal passages of the rat (50%), compared to man (8%) 
[386]. Insulin solutions were made fresh weekly from 100 U/mL vials (Humalog®, 
insulin lispro, Lilly; Levemir®, insulin detemir, Novo Nordisk) and diluted into 
sterile 0.9% saline.  
Blood glucose levels: To ensure that the intranasal delivery did not result in 
reduced peripheral glucose levels, and to test whether stress from the acute 
restraint procedures (DecapiCone®) could elevate blood glucose levels, we 
measured blood glucose (FreeStyle Lite glucometer; Abbott Laboratories, Abbott 
Park, IL) from dorsal tail veins in a subset of aged animals either exposed with 
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intranasal Levemir® (n = 5 from each treatment group) or Humalog® (n = 3), 
both before and approximately 1 hour after dosing (see supplemental Table 1). 
Animal behavior treatment groups and Morris water maze (MWM) 
procedures: Two cohorts of F344 animals were used for behavioral 
characterization (supplemental Fig. 1B). One cohort of animals (n = 50) was used 
to test the impact of long-acting insulin Levemir® at 3 different doses (low, 
medium and high; n = 10 per group) compared to an intranasal saline young 
group (3 months; n = 10) and an intranasal saline aged group (21 months old; n 
= 10). A second cohort of aged animals (n = 20) was used to test the impact of 
short-acting insulin Humalog® against saline (n = 10 per group). For analysis, 
behavioral data from the two aged saline control groups in both cohorts were 
combined because memory performance on probe day was similar (path length 
to goal, p = 0.89 and cumulative search error, p = 0.913). One aged animal in the 
saline group died during acclimation prior to initiation of behavioral testing. The 
remaining 69 animals where trained on the MWM. Animals were considered 
visually impaired or unable to learn the task if they could not find the platform on 
all 3 of the trials on the cue day (visual platform) and at least one of the 
remaining 3 training days. Based on these conditions, 2 aged Humalog® animals 
and 3 aged low-dose Levemir® animals were removed from the analysis. 
Behavioral results are therefore presented on 64 animals, 10 young saline, 19 
aged saline, 8 aged low-dose Humalog® (10 IU/day), 7 aged low-dose Levemir® 
(10 IU/day), 10 aged medium-dose Levemir® (20 IU/day), and 10 aged high-
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dose Levemir® (40 IU/day). On cue day, no significant differences were found 
across any of the groups on measures of path length (1-way ANOVA, p>0.05) 
and swim speed across insulin dose (1-way ANOVA, post-hoc p>0.05), indicating 
motivation and motor activity were likely similar. 
Insulin or saline treatment in both cohorts was initiated 4 days prior to the 
initiation of training (sup. Fig. 1B) and was delivered 1-3 hours before testing on 
the MWM. The MWM protocol has been published elsewhere [380, 387], but 
briefly, water temperature was maintained at 26-27oC, and black liquid tempera 
paint was used to make the water opaque and hide the submerged escape 
platform (~1.5 cm below water surface). A Videomex-V acquisition system and 
water maze analysis software (version 4.64, Columbus Instruments, Columbus, 
OH, USA) were used to track and measure animal movements. Animals were 
allowed 60 s to find the platform, after which they were guided to it. Each animal 
stayed on the platform for 30 s before returning to a heated holding chamber for 
about 2 min. On cue day, a white cup hanging above the partially submerged 
platform helped orient the animals. Animals were subjected to 3 trials per day 
(semi-random drop location for each trial) for cue and training days. Twenty-four 
hours after the last training day, a probe trial was initiated with the platform 
removed (60 s max swim time). Swim speed was derived from the distance 
travelled over time on the last trial of the third training day and on the first trial of 
the cue day. On all cue and training days the inter-trial interval was 
approximately 150 s. All behavioral experiments were conducted with the 
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experimenters blind to the treatment groups using color coding of the insulin and 
saline vials. 
Electrophysiology: Hippocampal slices were used across two 
electrophysiological setups, one monitoring extracellular field potentials and, the 
other measuring intracellular potentials (e.g., AHP). All data were acquired using 
pClamp 8.0 (Molecular Devices MDS, Toronto, Canada) through a Digidata 
1320A A/D converter (Molecular Devices). Potentials (e.g., amplitude and 
duration of AHPs, field EPSPs) were quantified off-line using Clampfit (Molecular 
Devices). Nineteen of the twenty behaviorally characterized aged animals 
(second cohort used to test the impact of short-acting insulin Humalog® against 
saline) were used 2-5 weeks after the last day of behavioral characterization to 
determine the impact of single intranasal insulin dose in vivo. From those, a total 
of 30 slices used for extracellular field potential recordings (Fig. 2D and 2E) and 
13 cells used for intracellular recordings (Fig. 2B and 2C) were used for statistical 
analyses and are presented using an n of 1 per cell/slice. In data presented in 
figure 3, 16 Sprague-Dawley animals (2-6 months old) were used to monitor the 
impact of zinc and Humalog® ex-vivo both extracellularly and intracellularly (30 
slices and 23 cells, respectively). Work presented in figure 4 (intracellular 
physiology only) is compiled from a total of 17 F344 male rats split into young (n 
= 8; 3 months) and aged (n = 9; 22 months). This last group of animals yielded 
recordings from 6 cells for young ACSF, 8 cells from young Apidra®, 6 cells for 
aged ACSF and 5 cells for aged Apidra®.  
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Figure 2.1 Morris water maze spatial learning and memory task. 
 (A)  Path length to submerged goal platform on the initial 3 days of training 
showed improved performance across all groups tested (RM ANOVA p<0.0001), 
however, no group effect was seen. On probe day, with platform removed, 
animals receiving low doses of insulin (Humalog® or Levemir®) showed reduced 
path lengths to goal (B) and improved memory performance based on reductions 
in cumulative search error (C). Analysis of swim speed measured on the third 
training day shows aged F344 animals are slower (note no effect of insulin dose 
on speed (D)). Means ± SEM are shown.  Asterisks indicate significant 
differences from the young saline group at p<0.05; pound sign indicates a trend 
(p=0.059) in comparison to the young saline group. 
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Figure 2.2 Impact of in vivo intranasal Humalog® on intracellular and 
extracellular physiology. 
 
(A) Representative intracellular recording of the AHP following a series of 4 
action potentials (truncated to emphasize the AHP). The mAHP (B) and sAHP 
(C) amplitudes recorded 3-7 hours after intranasal Humalog® in F344 rats were 
not significantly different. EPSP amplitudes (D) and I/O slopes (E) when recorded 
extracellularly 3-7 hours after intranasal Humalog® also were not significantly 
altered. Means ± SEM are shown. 
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Figure 2.3 Impact of ex vivo Humalog® and zinc on the AHP. 
(A) Representative voltage trace of the AHP recorded in a cell from an ACSF 
treated slice (black) and a Humalog® treated slice (1 nM, grey). Data are derived 
from young Sprague-Dawley animals. Traces are truncated to emphasize the 
AHP. Significant reductions in the sAHP amplitude (C) and duration (D) were 
seen in response to Humalog® as well as zinc. Note that zinc and low 
concentration Humalog® seem to work more robustly on the sAHP (only a trend 
was noted for the mAHP (B)). No significant effect was detected during 
extracellular recording of field EPSP amplitudes (E) or slopes of the I/O curve 
(F).  Means ± SEM are shown. 
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Figure 2.4 Zinc-free Apidra® reduces the AHP ex vivo. 
 
The mAHP amplitude is shown in (A) and the sAHP amplitude is shown in (B). 
Means ± SEM are presented in response to 1nM Apidra®. These data are taken 
from young and aged F344 rats. Asterisks indicate significant age-dependent 
increases in the mAHP and sAHP, and pound signs illustrate significant insulin-
mediated reductions in the AHP. Again, the impact of insulin seems more robust 
on the sAHP compared to the mAHP. These recordings were obtained with 4.5 
mM glucose in the ACSF.  
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Figure 2.5 Intranasal insulin delivery and experimental timeline. 
 
(A) This photograph shows a supine aged F344 rat during intranasal insulin 
delivery. The animal is held in place temporarily in a decapicone® with the head 
gently restrained. Note that the pipette tip is not inserted into the naris but 
presented at the entrance of the right naris. (B) Timeline used for behavioral 
(Morris water maze – MWM) and electrophysiological characterization presented 
in figures 1 and 2 using two cohorts of F344 rats. T1, T2 and T3 are initial 
training days on the MWM and are followed with a 24 h memory recall task 
(Probe). Each red triangle represents a consecutive day for intranasal insulin 
delivery in 2 different cohorts of animals. All animals were treated/ handled 
similarly across cohorts, and received 11 saline or insulin doses. Animals in 
cohort 2 were also used 2-5 weeks after behavioral characterization, to test the 
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electrophysiological impact of intranasal Humalog® in vivo. Electrophysiology 
data presented in figures 3 and 4 are derived from Spraque-Dawley and F344 
animals, respectively.  
Table 3. Blood glucose analysis. 
  Saline  10 IU Levemir® 
20 IU 
Levemir® 
40 IU 
Levemir® 
40 IU 
Humalog® 
  (n=5) (n=5) (n=5) (n=5) (n=3) 
Pre-Dose 73.2 ± 2.9 72.6 ± 6.2 70.8 ± 7.2 75.2 ± 3.8 65.3 ± 2.0 
Post-Dose 82.0 ± 3.7 82.2 ± 4.0 74.2 ± 6.5 78.4 ± 5.3 82.3 ± 6.0 
 
 
Numbers represent mean ± SEM peripheral glucose levels (mg/dL) taken before 
(Pre-Dose) and 30-90 min after intranasal insulin Levemir® or Humalog® 
delivery (Post-Dose). The number in parentheses represents the number of aged 
animal tested in each group. Intranasal insulin (Levemir® or Humalog®) did not 
reduce peripheral blood glucose levels. 
 
Field potentials:  Rats were anesthetized with Isoflurane® prior to decapitation. 
Brains were quickly removed and placed in oxygenated artificial cerebro-spinal 
fluid (ACSF) of the following composition (in mM): 114 NaCl, 3 KCl, 10 Glucose, 
1.25 KH2PO4, 26 NaHCO3, 8 MgCl2, 0.1 CaCl2. Hippocampi were sectioned 
(coronal) with a Vibratome® 3000 (Bannockburn, IL) set at 400 µm. Slices were 
transferred to an interface-type recording chamber (static) containing oxygenated 
recording ACSF of the following composition (in mM): 114 NaCl, 3 KCl, 10 
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Glucose, 1.25 KH2PO4, 26 NaHCO3, 2.5 CaCl2 and 1.3 MgCl2. The recording 
chamber was kept at 32° C and warm moist 95 % O2/ 5 % CO2 was continually 
delivered to the chamber. Bipolar synaptic stimulation was delivered through a 
SD9K stimulator (Astro Med Inc., Grass Instr., Warwick, RI). Input/output curves 
(I/O) were recorded using a series of increasing voltage steps. The relationship 
between stimulus intensity and EPSP amplitudes (prior to dendritic spike 
contamination) was fit (linear, r2>0.9) to yield a measure on the slope of the I/O. 
Data are also reported as the absolute amplitudes of the EPSPs measured as 
the maximum deflection from baseline. Insulin (1, 100, 500 nM Humalog®) 
and/or zinc treatment (130 nM – see AHP-intracellular recordings) under these 
conditions was initiated 1 hour after placing the slices in the chamber 
(compounds remained in the chamber for the duration of the experiment.  
AHP-Intracellular recordings: Hippocampal slices (350 µm) were transferred 
from the static chamber and placed in a perfusion chamber (RC22C, Warner 
Instruments, Co., Hamden, CT) and maintained in a continuous flow of 
oxygenated ACSF pre-heated at 32°C using a TC2Bip/HPRE2 in-line heating 
system (Cell Micro Controls, Northfolk, VA). The ACSF contained 2 mM CaCl2 
and 2 mM MgCl2 and in some experiments (Figure 4 only), the traditional 10 mM 
glucose concentration was replaced with 4.5 mM glucose. This was done to test 
whether higher glucose concentrations altered insulin sensitivity. We chose 4.5 
mM to help maintain tissue health and physiology for extended hours [388], to 
approximate values in anesthetized preparations [389], and to consider 
 
54  
fluctuations in brain glucose levels across a day [390]. As previously described, 
cells were impaled with sharp microelectrodes filled with 2M KMeSO4 and 10mM 
HEPES, pH 7.4 (tip resistance 90-120 MΩ) [377]. Recordings of membrane input 
resistance (IR) were obtained in response to 800 ms, 200 pA hyperpolarizing 
current injections using an Axoclamp 2B amplifier (Molecular Devices, MDS, 
Toronto, Canada) while holding the cell at -70 mV. To generate an 
afterhyperpolarization (AHP) cells were held at -65 mV (baseline) and 
depolarized with a 100 ms current injection to generate four Na+ action 
potentials. The medium AHP (mAHP) was measured as the peak 
hyperpolarization immediately after the offset of the depolarizing current injection, 
the slow AHP (sAHP) was measured 800 ms after the end of the current 
injection. The AHP duration was measured from the end of the depolarizing step 
until return to baseline.  
Several concentrations and formulations of insulin were tested ex vivo by 
addition to the solution bathing the hippocampal slices. Humalog® 
concentrations of 1, 100, and 500 nM were used. A zinc (ZnCl2) concentration of 
130 nM was used to mirror levels of free zinc attained in 250 nM Humalog®. 
Apidra® (insulin glulisine, Sanofi, a zinc-free insulin formulation) was used at 1 
nM and results were compared to ACSF. Under these experiments, Apidra® was 
used to treat slices both in the static chamber and during recording of the AHP. 
Apidra® was continuously perfused into the flow of the oxygenated recording 
ACSF using a precision perfusion pump (Orion Research, Model 341B, Boston, 
 
55  
MA) and resulting in a final concentration of 1 nM (diluted in sterile saline once a 
week from the 600 uM stock). Only neurons with input resistance > 25 MΩ, 
holding current < 500 pA and action potentials reaching above zero mV were 
included in the analysis. 
Statistics: Statistical analyses testing for significance (p<0.05) of main factors 
and interactions used a 1-way or a 2-way ANOVA as well as a t-test design 
(some electrophysiology). Fisher’s PLSD was used for post-hoc comparisons. All 
tests were conducted using StatView statistical package (version 5, Cary, NC) or 
GraphPad Prism V5 (San Diego, CA). Together the behavioral and 
electrophysiological data presented here are derived from a total of 106 animals. 
 
2.3 Results 
Blood analyses. Several studies show that intranasal insulin either has no 
effect, or a moderate lowering effect (within the euglycemic range) on peripheral 
blood glucose [31, 367-369, 383, 391, 392]. A 2-way RM ANOVA shows 
intranasal insulin did not alter peripheral blood glucose levels in a subset of the 
aged animals (n = 5/group) 30-90 min after intranasal insulin Levemir® delivery 
(supplemental Table 1). In another group of aged animals, 40 IU Humalog® also 
was unable to alter blood glucose levels. This result is consistent with transport 
of insulin to the perivascular space around blood vessels, indicating the hormone 
may not have crossed into the blood stream [34, 386]. 
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Behavioral analyses.  All groups learned to find the platform in the MWM as 
demonstrated by a significant decrease in path length to goal across the first 3 
days of training (F(2,116)=27.2; p<0.0001). During this learning phase, path length 
(Fig. 1A) however, showed no significant differences across groups with age or 
intranasal insulin dose (2-way RM ANOVA). As shown previously [387, 393], 
analysis of swim speed revealed a significant group effect (F(5,58)=12.5; 
p<0.0001) with post-hoc tests indicating aged animals swam at slower speeds 
compared to young animals, but no difference between the insulin treatment 
groups was noted (Fig. 1D). Latency to target, as predicted from slower speeds 
in aged animals, was significant across 3 days of training (F(2,116)=28.9; 
p<0.0001), with increased latency seen in all aged animals compared to young 
saline animals (data not shown). Because of this decrease in swim speed we 
chose to assess search errors and quantify memory performance on the probe 
day (no platform) using a proximity measure analysis. This approach is less 
dependent on swim speed than latency and is tabulated using a cumulative 
search error derived from the subject’s distance to the platform summed over the 
time to reach the platform and is then subtracted from an ideal path (straight 
line); smaller values are indicative of better performance [394]. 
 
Compared to the learning component of the task, the 24 h memory recall 
component measured during the probe trial (1-way ANOVA) revealed a 
significant group effect on path length to goal (F(5,58)=2.9; p<0.05) and on 
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cumulative search error (F(5,58)=3.3; p<0.05). Post-hoc analyses identified a 
significant increase on path length and cumulative search error in the aged saline 
(p<0.05) and aged medium-dose Levemir® (p<0.005) groups compared to the 
young saline group (Figs. 1B and 1C). A trend (p=0.059) for improved 
performance was found for the high-dose Levemir® animals on path length 
measures only.  Notably, no significant differences were found between young 
saline treated and aged animals treated with either low-dose Humalog® or low-
dose Levemir® on path length or cumulative proximal distance (Figs. 1B and 
1C), indicating that the lower dose intranasal insulin significantly reduced age-
dependent memory loss. Additional post-hoc analyses on memory performance 
in aged animals, comparing combined low dose insulins (Humalog® and 
Levemir®) with combined medium- and high-dose Levemir®, revealed significant 
improvement in the low-dose insulin group on path length (F(1,33)=5.25; p<0.05) 
and cumulative search error (F(1,33)=5.91; p<0.05). Thus, each of the different 
insulin formulations (Humalog® and Levemir® at low-doses) improved 
performance despite being administered to two separate cohorts of aged 
animals, indicating reproducibility of the insulin effect, and it appears lower, 
rather than higher doses of insulin are able to redress cognitive decline with 
aging.  
 
Electrophysiology analyses. Based on improved memory recall observed in 
aged animals treated with low-dose insulins, we next characterized the effects of 
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in vivo intranasal insulin on hippocampal electrophysiology in a subset of the 
Humalog® treated animals that were behaviorally characterized. Supplemental 
Table 2 shows that passive membrane properties were not different between 
groups and suggests cells with comparable baseline characteristics were 
analyzed. Intracellular recording of CA1 pyramidal neurons were obtained from 
animals treated with intranasal saline or Humalog® (see Methods). 
Approximately 3-7 hours following intranasal insulin delivery the Ca2+-dependent 
AHP was not significantly different between groups (Figs. 2B and 2C; t-test). This 
was true for measures of AHP amplitude (medium and slow AHP) and duration 
(not shown). Extracellular synaptic potentials also showed no significant 
difference across groups (Figs. 2D and 2E; t-test). EPSP amplitudes measured 
at 33% of the I/O were slightly larger in the Humalog® treated animals and I/O 
slopes based on EPSP amplitude measures were somewhat reduced (Figs. 2D 
and 2E, respectively, p<0.1). These results are surprising given our prior report 
that insulin application to hippocampal slices reduces the AHP [380]. In the prior 
study, however, hippocampal slices were perfused for 15 minutes with insulin 
and then studied electrophysiologically. The results obtained in the present study 
raise the possibility that the delay between intranasal insulin exposure and 
electrophysiological recording (3-7 h) was too long and that the effect of insulin 
on the AHP may have dissipated. Thus, to confirm that insulin must be present in 
order to alter hippocampal physiology, we tested a range of ex-vivo insulin 
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concentrations and formulations on hippocampal slices from a separate group of 
animals. 
  
We used young animals in the next series of experiments, and examined three 
different doses of Humalog®, comparing Humalog®’s actions to zinc and ACSF. 
In most insulin formulations, zinc is used to promote hexamer formation and 
prolong stability and duration of action in vivo. However, zinc is also known to 
modify ion flux across neuronal membranes, reducing activity at NMDA and 
GABAA receptors, ion channels associated with memory-related processes 
[reviewed in 395]. Extracellular recordings in the presence of zinc or Humalog® 
showed that neither EPSP amplitudes, nor I/O slopes were significantly altered 
when compared to ACSF controls (Figs. 3E and 3F; 1-way ANOVA). Similarly to 
data shown in figure 3, these results indicate little if any, effects of insulin on 
extracellular postsynaptic potentials.  
 
Intracellular recordings obtained from the same group of animals showed that the 
Ca2+-dependent AHP was sensitive to treatment with zinc or insulin. As 
previously reported, measures of postsynaptic excitability demonstrated the 
sensitivity of the AHP to both zinc [396] and insulin [380]. A main effect of 
treatment on the slow AHP (F(4,18)=3.34; p<0.05) and its duration (F(4,18)= 4.49; 
p<0.02) was seen across 5 groups of recorded cells (Figs. 3C and 3D). Albeit 
being somewhat reduced, the mAHP was not significantly altered by insulin (Fig. 
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3B). These results suggest a component of the insulin effect on the AHP could 
well be mediated by zinc found in this insulin formulation. To test the direct 
impact of ex vivo insulin on the AHP, we next investigated a zinc-free formulation 
of insulin (Apidra®).  
 
In this next series of experiments we obtained hippocampal slices from young 
(n=8) and aged (n=9) F344 rats and focused exclusively on intracellular 
potentials and the response to ex vivo Apidra® exposure (1 nM). Further, a 
recent study identified that 0.1-100 nM exogenous insulin concentrations could 
reliably elicit dose-dependent activation of the insulin signaling pathway in human 
brain tissues [20], and approximated physiological levels near 1 nM. For these 
reasons, we used 1 nM Apidra®. As previously reported [377-379, 397] and 
shown here (Fig. 4), mAHP and sAHP amplitudes recorded in CA1 pyramidal 
neurons were increased (F(1,24)=17.6, p<0.0005; F(1,24)=4.7, p<0.05, respectively) 
in aged, compared to young animals (2-way ANOVA). Treatment with the zinc-
free Apidra® insulin significantly reduced the AHP in slices from both young and 
aged rats as indicated by a main effect of treatment on the mAHP (F(1,24)=32, 
P<0.0001) and the sAHP (F(1,24)=29.1, p<0.0001). However, the Apidra® -
mediated AHP reduction was larger in aged animals compared to young animals 
(Figs. 4A and 4B) as evidenced by a significant interaction term in the 2-way 
ANOVA (F(1,24)=10.9, p<0.005 for the mAHP). These results are consistent with 
our prior work using Humalog® showing that the hippocampal AHP is sensitive to 
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insulin [380]. In the experiments presented here however, it is clear that insulin 
alone has a direct effect on the AHP, and that this effect persists even when 
lower, more physiological glucose levels are used in the ACSF (experiments in 
Figure 4 were conducted with 4.5 rather than the typical 10 mM glucose 
concentration - see Methods). Finally, it is interesting to note that Apidra® did not 
alter holding current when compared to control cells (sup. Table 2), indicating 
insulin is neither activating nor inhibiting a tonic current near resting potential. 
 
 
2.4 Discussion 
Studies in humans have shown that intranasal insulin has promising cognition 
enhancing effects, alleviating, and perhaps even slowing the progression of age-
related neurodegenerative disorders. However, the mechanisms underlying 
insulin’s effects in the brain are unclear. In order to identify potential 
mechanisms, we treated aged rodents with intranasal insulin, attempting to 
model aspects of the clinical trials reporting on the beneficial impact of intranasal 
insulin. Here, we describe physiological actions of insulin in the brain, highlighting 
a potential new mechanism of action of insulin on hippocampal function in both 
young and aged rats. This first analysis of intranasal insulin in aged animals 
demonstrates that intranasal insulin improved memory recall in aged F344 rats. 
We show that the effect on memory was observed in two separate cohorts of 
animals, using two different insulin formulations (Humalog® and Levemir®) 
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delivered at relatively low dose (0.0715 IU/day/rat). Thus, these studies also 
demonstrate reproducibility of the effect of insulin on behavior. We also show that 
the Ca2+-dependent afterhyperpolarization (AHP), and in particular the slow 
AHP, a Ca2+-related biomarker of brain aging which increases with age and 
cognitive decline, is reduced by acute insulin exposure in aged animals and 
could well represent a novel target of brain insulin underlying the improvement 
seen in memory recall.  
Long-acting insulin (Levemir®) was as effective as short-acting insulin 
(Humalog®) on memory recall in aged animals, inducing levels of performance 
indistinguishable from those seen in young animals. Levemir®’s long duration of 
action is dependent on the presence of albumin in the periphery and a fatty acid 
modification of the insulin structure, increasing its’ affinity for albumin. 
Humalog®’s shorter duration and faster onset are due to amino acid 
modifications in the β-chain of the insulin molecule. Because both versions of 
insulin were able to reverse cognitive decline to a similar degree in aged animals, 
our results suggest both insulins were able to gain access to the brain following 
intranasal administration despite structural differences. While results from clinical 
studies in memory-impaired older adults have reported improved word recall 
within 15 min post intranasal delivery [398], a prior clinical study on younger 
adults demonstrated the superiority of a faster acting insulin (Novolog®) 
compared to regular insulin (Actrapid®) on delayed word recall after 7 weeks of 
intranasal 160 IU/day Novolog® [392]. Using shorter delays (i.e., 10 min) a 
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recent study reveals 40 IU intranasal insulin delivery to young adult males 
improves odor-cued spatial memory [399]. Clearly, the memory enhancing 
effects of insulin are depend on treatment regimen (acute vs. subchronic), but 
also on the age and gender of the subject [400], as well as on the insulin 
formulation used [382, 401]. As mentioned above, a single, acute intranasal dose 
of insulin is capable of enhancing memory in humans and our 
electrophysiological studies showing an acute action of insulin on the AHP 
indicate that insulin can have rapid effects on neuronal processes critical to 
memory (see below). However, in the current study, it is unclear whether the 
effects on cognition observed here were due to an acute action of insulin (i.e., the 
dose received 1-3 h prior to memory testing), or the result of the cumulative daily 
treatments received over the course of 8-11 days.  
he decrease in the AHP by insulin was observed in field CA1 of the 
hippocampus, a synaptic zone which plays a key role in memory processing. 
Decreasing the AHP in this structure would be expected to increase neuronal 
excitability and facilitate throughput during physiological activation. Consistent 
with this, exogenous insulin increases excitatory neurotransmitter receptor 
trafficking including NMDA and AMPA receptors [88, 358, 359, 402], thus 
promoting network activation. Furthermore, pure insulin has been shown to 
activate an inward current and depolarize hypothalamic neurons via activation of 
transient receptor potential channels, providing supporting evidence that insulin 
raises excitability [403]. However, recent results provide evidence that insulin or 
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other therapies that raise insulin (exendin-4 and glucagon-like peptide-1), 
increase functional GABAA conductances in CA1 [352] as well as in CA3 
pyramidal neurons [404]. This observation is in line with prior reports of 
enhanced GABAA function in response to insulin, a resulting decrease in synaptic 
activity [350, 351] and a long-lasting enhancement of inhibitory post-synaptic 
currents (IPSCs) [405].  The net result, therefore, of enhancing both steady-state 
hyperpolarizing (GABA-mediated) and short term depolarizing forces (e.g., 
reduced AHP or direct depolarization) could well increase synaptic signal-to-
noise, thereby improving throughput and neuronal communication. Clearly, as 
seen in hypothalamic arcuate nucleus neurons, it is important to note that 
insulin’s modulatory influence on membrane potential/ excitability, is insulin 
formulation dependent, as well as cell-type specific [403]. 
To extend slice health and allow for extended neuronal recordings, high glucose 
concentrations (10 mM) are commonly used in the ex-vivo hippocampal slice. 
However, this superphysiological glucose concentration may alter insulin 
sensitivity in the brain. For this reason, we used lower glucose levels in some 
experiments while maintaining tissue health (see Table 2), and more closely 
approximating physiological glucose levels. Importantly, significant AHP 
reduction was seen irrespective of recording conditions (10 or 4.5 mM glucose). 
Thus, the results presented here appear compatible with potential effects of 
insulin on hippocampal neurons in vivo.  
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The placebo group in almost all clinical trials studying the impact of intranasal 
insulin on memory function is generally exposed to either saline or HOE-31, a 
dilution buffer that does not contain zinc. Given that all insulin formulations 
except Apidra® contain zinc, our results showing that Apidra® is capable of 
reducing the AHP in hippocampal neurons ex vivo could have clinical 
significance. These data are consistent with insulin per se being able to alter 
hippocampal physiology, and suggest that insulin and not zinc may be 
responsible for the CNS effects of intranasal insulin on memory. Clearly further 
clinical trials with Apidra® appear warranted. 
Because the AHP is dependent on a Ca2+-activated K+ conductance, the insulin-
mediated reductions in the AHP may be due to inhibition of Ca2+ influx [406] or 
inhibition of L-type Ca2+ channel currents as seen in pinealocytes [407]. Taken 
together, these results suggest insulin acts through the insulin receptor to reduce 
Ca2+-mediated functions possibly through PI3 kinase- or tyrosine kinase-
mediated phosphorylation of Ca2+ channel proteins. Indeed, insulin can enhance 
mitochondrial function and therefore, Ca2+ homeostasis through PI3 kinase 
mechanisms in the periphery [193]. Insulin also increases sarco-endoplasmic 
reticulum Ca2+-ATPase (SERCA) function in heart cells via an Akt (protein 
kinase B) pathway, and in neurons, insulin has been shown to reduce KV1.3 
potassium channel function [408]. Notably, all of these potential mechanisms are 
consistent with reductions in available Ca2+, and hence, reductions in the 
amplitude of Ca2+-dependent hyperpolarizing potentials.  
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Our data cannot address whether the beneficial actions of intranasal insulin on 
memory recall are mediated, in parts or in whole, by the effects of insulin on the 
AHP. While suggestive that this may be the case, we do not provide evidence to 
support this conclusion. Further, because young animals were not tested for the 
impact of intranasal insulin, future studies will be needed to test the hypothesis 
that the observed effect is age-selective, or generally nootropic. Finally, although 
a similar insulin dose yielded quantitatively similar enhancement on memory 
recall in two cohorts of aged animals, it is not clear that higher Humalog® doses 
might also be ineffective, similarly to higher Levemir® doses. 
The present results shed new light on a previously unrecognized insulin 
mechanism in the brain. Reductions in the AHP could enhance neuronal 
communication and might represent a pathway through which low dose 
Humalog® or Levemir® improve memory recall in aged animals. We show that 
insulin targeted the AHP, a Ca2+-mediated conductance, and reduced AHP 
amplitude and duration, elevations of which are characteristic of brain aging. We 
propose that facilitating insulin signaling restores Ca2+ homeostasis in aged 
animals, resulting in optimal levels of membrane excitability and synaptic 
plasticity, in part by limiting the amplitude and duration of the AHP in CA1 
neurons (Figs. 4 and 5). During aging, reductions in brain insulin levels and/or 
insulin receptor function (see Introduction) may help promote neuronal Ca2+ 
dysregulation, resulting in impaired membrane excitability and reduced synaptic 
plasticity (e.g., larger AHP). Clearly, given the reductions in insulin receptor RNA 
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and protein in the aged rodent [27, 111], greater occupation of the leftover insulin 
receptors with insulin could well offset reductions in signaling through these 
receptors, or may even slow the age-related reduction in insulin receptor density. 
Collectively, these results indicate robust associations between brain insulin, 
Ca2+ homeostasis, and aging-related cognitive decline, and suggest the value of 
further developing “insulin-raising” strategies for treating cognitive decline in age 
and disease, perhaps curbing the development of AD. 
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Chapter 3 Link between studies 
 
3.1 Intranasal insulin and cognition 
In the late1990s, several clinical studies suggested that diabetes is a risk factor 
for cognitive decline and AD [142, 409, 410]. Also, through population-based 
studies, it has become clear that dysregulation in insulin signaling increases the 
risk for cognitive decline with aging and AD [139, 411-417]. In addition, imaging 
studies have shown that diabetes patients have smaller hippocampi and that 
brain functional connectivity also changed compared to healthy individuals [418-
422]. Furthermore, studies have found that insulin receptors are widely 
expressed in different regions of the brain and play a vital role in regulating 
whole-body glucose metabolism, energy balance, and neurotransmission in the 
brain [423]. In addition, aging can alter insulin and insulin receptor function, 
reduce pancreatic beta cells function, and reduce insulin secretion by pancreatic 
beta cells  [424, 425]. These studies ignited interest in the effects of insulin in 
the brain in the context of cognition and led the way for later research 
confirming that insulin is an important cognitive enhancer.  
Interest in the study of intranasal insulin has also stemmed from a number of 
clinical studies demonstrating that intravenous insulin infusion during clamped 
glucose conditions improved memory [15, 29, 137, 149]. Clearly, due to the 
danger of hypoglycemia, insulin infusion peripherally is not a feasible approach 
for treating AD. On the other hand, it has been shown that intranasal insulin 
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delivery targets the brain, bypassing the blood brain barrier, and without the risk 
of hypoglycemia [349, 426]. There are several ongoing intranasal insulin clinical 
trials, including study of nasal insulin to fight forgetfulness (SNIFF), intranasal 
insulin in children and young adults at risk of type 1 diabetes, intranasal insulin 
for the HAND (HIV-associated neurocognitive disorder), and intranasal insulin 
for stroke patients. My research is focus on the neuronal effects of intranasal 
insulin on the context of cognitive decline with aging.  
Intranasal administration of insulin appears to be one of the best methods to 
treat cognitive decline due to its minimal effect on systemic glucose levels and 
its acute improvements on hippocampal-dependent memory. Intranasal insulin 
enters the brain mainly through olfactory and trigeminal pathways [427-429]. 
Insulin binds to insulin receptors in various brain regions, including the 
hippocampus [430]. The hippocampus is well-known as a principle brain region 
for learning and memory. Normal insulin signaling of neurons within the 
hippocampus area is typically associated with healthy brain aging. Furthermore, 
deficiency in brain insulin signaling accelerates pathological brain aging and 
cognitive decline. The goal of intranasal insulin study in our lab is to achieve a 
greater understanding of the effects of insulin and insulin signaling pathways 
that might slow or reverse age-related memory decline and pathologies.  
We found that a repeated low dose of intranasal insulin had a positive effect on 
memory recall in aged F344 rats. However, medium and high doses of insulin 
did not have a beneficial effect on memory in aged F344 rats. This varying 
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outcome is in line with clinical intranasal insulin studies. Clinical studies show 
that intranasal insulin therapy improves memory maintainability in healthy and 
AD patients [32, 431]. Although intranasal insulin enhances memory in AD 
patients, varying outcomes arise from its clinical setting usage [431].  Men and 
women with AD respond differently to intranasal insulin dosages [36]. In 
addition, some clinical studies have reported that patients carrying at least one 
copy of the Apolipoprotein E4 (the strongest genetic risk factor for late onset 
Alzheimer’s disease) did not benefit from intranasal insulin treatment [37]. 
Hence, these clinical trials revealed that not everybody responds equally to 
intranasal insulin therapy. Based on both clinical and animal studies, different 
formulations and dosages of insulin, as well as gender and ApoE status in AD 
patients increase the outcome variability in intranasal insulin treatment. A clear 
understanding of the mechanisms underlying insulin actions in the brain will 
help address these varying outcomes and increase the efficacy and safety of 
using intranasal insulin to treat cognitive impairment. 
 
3.2 Insulin and Ca2+-dependent after hyperpolarization 
It is also well documented that the Ca2+-dependent AHP (Ca2+ related 
biomarker of brain aging) increases in aged and memory-impaired animals. The 
greater AHP is correlated with reduced neuronal excitability and learning ability 
[30, 184, 377, 379, 380, 432-437]. It is widely accepted that reducing the AHP is 
one viable pathway to enhance learning and memory in aging animals. Data 
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from our lab suggests that insulin reduces the AHP in CA1 neurons from young 
and aged rat hippocampal slices [30, 380]. These findings are in line with 
previous behavioral studies, suggesting that insulin therapy improves memory 
by reducing the Ca2+ dependent AHP [30]. However, the molecular 
mechanism(s) that result in such an interaction has not been studied in depth. 
Ca2+ and potassium are the main ions that influence the amplitude and duration 
of AHP. Here, I focused on the relationship between insulin and intracellular 
Ca2+ homeostasis. 
 
Another factor besides insulin that is related to cognitive decline in aging and AD 
is elevated intracellular Ca2+ concentration [187-191]. The two main sources of 
intracellular Ca2+ are Ca2+ influx via voltage-gated Ca2+ channels (VGCCs) on 
the plasma membrane and Ca2+ efflux via ryanodine receptors (RyRs) mediated 
Ca2+-induced Ca2+-release (CICR) on the endoplasmic reticulum. 
 
3.3 Voltage-gated Ca2+ channels dysfunction with aging 
Voltage-gated Ca2+ channels (VGCCs) are responsible for Ca2+ influx into the 
cytosol in response to membrane depolarization. VGCCs play a critical role in 
neuronal excitability, neurotransmission and Ca2+ signaling, which is important 
for learning and memory in healthy and disease states. All types of VGCCs are 
expressed in the hippocampus and involved in neuronal firing, action potential, 
and synaptic plasticity [438]. Furthermore, the density of plasma membrane 
VGCCs increases with aging and results in elevated intracellular Ca2+ levels, 
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which is toxic to neurons and leads to cell death [226, 439-441]. Earlier studies 
showed that elevated Ca2+ influx via VGCCs contribute to bigger AHP and 
cognitive decline in aged animals [184, 224, 437, 442, 444-446]. In addition, 
voltage-gated Ca2+ channel blockers have been shown to improve cognition in 
aged animals, as well as in dementia and AD patients [447-450]. Moreover, 
knockout of voltage-gated Ca2+ channels have a great impact on memory in 
aged animals [451, 452]. In hippocampal neurons, Ca2+ entry though VGCCs 
during membrane potential triggers Ca2+-induced Ca2+-release from 
endoplasmic reticulum via the ryanodine receptors, causing amplification of 
intracellular Ca2+ levels  [220, 377, 435, 453]. 
 
3.4 Ryanodine receptors dysregulation with aging 
Ryanodine receptors (RyRs), an intracellular Ca2+ release channel, is 
responsible for Ca2+ release from endoplasmic reticulum (ER) and triggers 
amplification of intracellular Ca2+ levels through RyR-medicate Ca2+-induced 
Ca2+-release (CICR). RyRs plays a vital role in maintaining intracellular Ca2+ 
homeostasis. Thus, RyR-mediated Ca2+ release is critical to cellular 
physiological events ranging from muscle contraction to learning and memory. All 
RyRs isoforms (RyR1-3) are expressed in the various regions of the brain, 
including the hippocampus, cerebellum, olfactory region and cerebral cortex, 
which are located within the presynaptic terminals of neurons. The RyRs 
channels have been found to show changes in functional efficacy during 
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aging/AD [136, 377, 435, 453-458] and influence the amplitude and duration of 
Ca2+ dependent afterhyperpolarization (AHP) [192, 377].  Additionally, increases 
in RyRs-mediated intracellular Ca2+ release through CICR mechanisms during 
aging results in loss of intracellular Ca2+ homeostasis, thus greatly influencing 
cognitive function [192, 377, 459].  
Taken together, age-related increases in RyRs-mediated intracellular Ca2+ 
release mechanisms are also responsible for larger AHP seen in memory 
impaired aged animals. Ultimately, lowering Ca2+ efflux via RyRs is important for 
reducing the AHP.  
 
However, a central question of whether insulin reduces VGCCs currents 
remains unanswered. Furthermore, it is not clear whether insulin affects RyRs 
function. To address these questions, the activity of VGCCs was recorded from 
neurons that were treated with acute (10 minute) insulin vs. control solutions. In 
parallel studies, Ca2+ imaging was used in cultured hippocampal neurons to 
evaluate the RyRs-dependent intracellular Ca2+ level changes in insulin treated 
neurons. Our approach helped us to delineate one of the many neuronal 
molecular mechanisms underlying insulin’s effect on memory through the 
reduction of AHP via regulating intracellular Ca2+.  
 
The following manuscript has been submitted to Neuroscience. 
In this manuscript, I continue to study the underlying mechanisms responsible 
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for the memory enhancing effects of intranasal insulin in aged animals. It is 
clear that Ca2+-dependent AHP is one of insulin’s neuronal targets from the 
previous study presented in this dissertation (Chapter 2). Those data led me to 
focus further on the relationships between insulin and hippocampal intracellular 
Ca2+, which influence the amplitude and duration of AHP. Voltage-gated Ca2+ 
channels and ryanodine receptors are major factors that contribute to 
dysregulation of intracellular Ca2+ homeostasis present in aged animals. 
Hence, I tested acute insulin’s effect on single live hippocampal neurons in 
culture using whole-cell patch clamping. In addition, insulin effects on resting 
and depolarization mediated intracellular Ca2+ transients were examined in the 
single live neurons using Ca2+ imaging techniques.  
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Synopsis 
Both insulin signaling disruption and Ca2+ dysregulation are closely related to 
memory loss during aging and increase the vulnerability to Alzheimer’s disease 
(AD). In hippocampal neurons, aging-related changes in Ca2+ regulatory 
pathways have been shown to lead to higher intracellular Ca2+ levels and an 
increase in the Ca2+-dependent afterhyperpolarization (AHP), which is 
associated with cognitive decline. Recent studies suggest that insulin reduces 
the Ca2+-dependent AHP. Given the sensitivity of neurons to insulin and 
evidence that brain insulin levels are reduced with age, insulin-mediated 
alterations in Ca2+ homeostasis may underlie the beneficial actions of insulin in 
the brain. Indeed, increasing insulin signaling in the brain via intranasal delivery 
has yielded promising results such as improving memory in both clinical and 
animal studies. However, while several mechanisms have been proposed, few 
have focused on regulation on intracellular Ca2+. In the present study, we further 
examined the effects of acute insulin on Ca2+ pathways in primary hippocampal 
neurons in culture. Using the whole-cell patch-clamp technique, we found that 
acute insulin delivery reduced voltage-gated Ca2+ currents. Fura-2 imaging was 
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used to also address acute insulin effects on spontaneous and depolarization-
mediated Ca2+ transients. Results indicated that insulin reduced Ca2+ transients, 
which appears to have involved a reduction in ryanodine receptor function. 
Together, these results indicate insulin regulates pathways to control intracellular 
Ca2+ which may be responsible for reducing the AHP and improving memory. 
This may be one mechanism contributing to improved memory recall in response 
to intranasal insulin therapy in the clinic. 
 
 
 
 
Keywords:  diabetes, intranasal, excitability, imaging, electrophysiology, aging  
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4.1 Introduction 
Aging is a major risk factor for Alzheimer’s disease (AD), and both brain aging 
and AD are characterized by a progressive decline in cognitive and memory 
function. A promising treatment for cognitive impairment seen in AD is to 
maintain or enhance insulin signaling in the brain. Insulin is a cognitive and 
neural modulator that is synthesized by pancreatic β-cells and enters the brain 
through the blood brain barrier [460-463]. In the periphery and in the brain, 
insulin has been shown to bind to insulin receptors and to regulate glucose 
uptake by inducing translocation of glucose transporters to the plasma 
membrane [464]. In aging or AD, declining insulin levels, insulin receptor 
numbers, and/or glucose transporters can lead to dysregulation in glucose 
uptake. This is evidenced by nearly two decades of research showing strong 
associations between diabetes, cognitive decline, and AD [16, 141-144]. At the 
cellular level, brain insulin deficiency and reduction in insulin signaling, perhaps 
mediated by insulin resistance, could represent one of the altered pathways 
linked to altered memory function or synaptic communication during aging and 
AD [15-20, 30]. Underlying this relationship is evidence that insulin receptor 
numbers and their functions are decreased in aging and AD animal models [111, 
346, 465, 466]. As such, interruption of insulin production or in insulin receptor 
activity may cause cognitive decline [323]. One approach designed to combat 
this reduction in insulin signaling that has received much interest in the clinic is 
the use of intranasal insulin delivery to selectively increase ligand concentration 
in the brain [349]. 
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Intranasal insulin therapy has been shown to improve memory function in AD 
patients [32, 431]. The intranasal route of insulin administration raises insulin 
acutely in the central nervous system without much risk of peripheral 
hypoglycemia [30, 367, 426, 467, 468]. Importantly, it significantly enhances 
memory in both healthy individuals and AD patients [31, 33-35, 37]. In aging and 
AD animal models, the positive impact of intranasal insulin in combating cognitive 
decline has also been reported [30, 381, 467, 469-473]. The mechanisms of 
action in the brain, and specifically on neurons of the hippocampus where insulin 
plays a recognizable role in learning and memory [28, 111], remain however, 
largely unknown.   
Because previous work on mechanisms of cognitive aging has focused on Ca2+ 
dysregulation in hippocampal neurons providing evidence of enhanced Ca2+ 
levels [377, 439, 445, 474-476] and voltage-gated Ca2+ channels (VGCC) 
activity [224, 432, 445, 477], we focused on studying two well-characterized 
Ca2+ sources in hippocampal neurons in culture. The rationale for this approach 
was based on recent evidence from our lab that insulin acutely reduces the 
Ca2+-dependent afterhyperpolarization (AHP) in neurons recorded from 
hippocampal slices [30, 380]. The AHP is a hyperpolarization potential that is 
enhanced in aging, limits neuronal firing, and is associated with cognitive decline 
[379, 380, 433, 478]. The larger AHP seen in aging is mediated in part by an 
increase in the density of L-type voltage gated Ca2+ channels (L-VGCC) [224] 
and by Ca2+-induced Ca2+-release (CICR) through activation of  RyRs [377, 
479, 480]. Together, these two sources of Ca2+ contribute to elevated 
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intracellular Ca2+ levels, larger AHPs and altered synaptic communication.  
Thus, here, we tested the hypothesis that acute insulin (glulisine, zinc-free and 
fast acting) could reduce Ca2+ levels, or stabilize Ca2+ homeostasis by altering 
VGCC function and/ or ryanodine receptor (RyR) function. To address these 
questions, we used patch clamp recording of VGCCs with rapid drug delivery, 
as well as Fura-2 imaging during depolarization in the presence or absence of 
RyR blocker. Our results indicate that insulin is able to reduce Ca2+ levels 
during periods of neuronal depolarization and that this is mediated, at least in 
part, by reductions in VGCC and RyR function. These two aging-sensitive 
neuronal Ca2+ targets are therefore also sensitive to the actions of insulin and 
could represent novel therapeutic targets for cognitive decline in aging and/ or 
AD. Re-establishing Ca2+ homeostasis represents a mechanism by which 
insulin and by extension, intranasal insulin, may offset learning and memory 
dysregulation in vivo. 
 
 
4.2 Experimental procedures 
Cell culture: Hippocampal mixed (neuron/glia) cultures were prepared as 
described previously [439, 481, 482] and established from (E18) Sprague-
Dawley rats. E18 pups and hippocampi were dissected under a microscope in 
ice-cold Hank’s balanced salt solution (Thermo Fisher Scientific Inc., MA, USA) 
supplemented with 4.2 mM NaHCO3, 10 mg/L gentamicin and 12 mM HEPES 
(pH 7.3). Hippocampi were transferred to a 37oC 0.25 % Trypsin EDTA solution 
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(Thermo Fisher) and left at room temperature for 11 minutes. Trypsin was 
removed and the hippocampi were washed three times with Minimum Essential 
Medium (MEM). Hippocampi were then titrated, and diluted with MEM to the 
desired final concentration (5-7 x 105 neurons/ml) before being plated onto 35 
mm poly-L-lysine coated dishes. Cultured neurons were incubated (36°C, 5% 
CO2, 95% O2) for 24 h before the first medium exchange. At this time, half of the 
medium was replaced with 90% SMEM supplemented with 10% Horse serum. 
After three days in vitro (DIV), half of the medium was replaced with SMEM, 
horse serum, 5-Fluoro-2-Dioxyuridine and uridine to stop glial cell growth. At DIV 
10, a sodium bicarbonate solution (200 uL) was added to help maintain pH and 
limit evaporation. 
For whole-cell recording experiments, plastic culture dishes were used (Corning 
Inc., Corning, NY, USA) and for Ca2+ imaging experiments, glass bottom culture 
dishes (Mattek Crop., Ashland MA, USA) were used. All data presented were 
collected between DIV 13 and 17, and experiments were conducted following a 
24 h exposure to lower glucose-containing MEM (5.5 mM; MEM with no added 
glucose). This was done to maintain normal glucose oxidation rates and insulin 
sensitivity [482]. All data presented were obtained at room temperature. 
VGCC recording solution: For whole-cell, external recording solution of VGCC 
currents, was as follows (in mM): 111 NaCl, 5 BaCl.H2O, 5 CsCl, 2 MgCl2, 10 
glucose, 10 HEPES, 20 TEA.Cl.H2O, pH 7.35 with NaOH, and 500 nM 
tetrodotoxin (TTX) was added before recording to inhibit Na+ channels. The 
internal pipette solution (in mM): 145 CH4O3S-methanesulfonic acid, 10 HEPES, 
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3 MgCl2, 11 EGTA, 1 CaCl2, 13 TEA.Cl.H2O, 14 phosphocreatine Tris-salt, 4 
Tris-ATP, 0.3 Tris-GTP, pH 7.3 with CsOH. All solutions were sterile filtered.  
Drugs and solution application: External solutions were delivered using a rapid 
solution exchange system (SF77A - Warner Instruments Corp. Hamden, CT, 
USA) positioned approximately 400 um above the cell being recorded. Flow rate 
was set to 0.3 mL/min and a control solution supplemented with TTX was used to 
establish baseline recording (~10 min) during which passive cell membrane 
properties were obtained (e.g., membrane resistance, capacitance, access 
resistance), and currents were allowed to run up. Rapidly switching the position 
of the tubing delivering the solutions above the recorded or imaged cell allowed 
us to tightly control the environment and deliver either insulin, KCl (50 mM), 
ryanodine (20 uM), a high-affinity small peptide interacting with insulin (affibody, 
ab31906, Abcam, Cambridge, MA, USA; 100 ng/mL, 500 ng/mL, or 1 ug/mL), or 
an insulin receptor antibody (S961, Phoenix Pharmaceuticals Inc., Burlingame, 
CA., USA; 500 ng/mL). Insulin glulisine (10 nM, a fast acting, zinc-free insulin) 
was prepared weekly in external recording solution from a 6 uM stock (Apidra® 
600 uM, Sanofi-Avantis US. LLC, diluted in sterile saline). This concentration was 
chosen based on our previous results from our lab [30, 380]. 
Whole-cell recording and analysis:  To minimize capacitance artifacts, whole-cell 
patch-clamp electrodes were coated with polystyrene Q-dope before recording 
(see Table 1 for membrane and electrode properties). The culture dish was 
rinsed with external solution twice and then supplemented with TTX. To allow for 
currents to stabilize, all data were recorded 5-10 min after the whole-cell 
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configuration was achieved. Current/voltage (I-V) relationships (-60 to + 30 mV) 
were used to identify the voltage step eliciting the maximal current amplitude. 
This voltage was used for each cell in the study in order to compare data at the 
peak of the I-V relationship (150 ms depolarization). Cells were either held at -70 
mV (150 ms) or -40 mV (350 ms) and currents were elicited at the maximal peak 
response. All currents were leak subtracted using 5-8 scaled hyperpolarizing 
sub-pulses. Because insulin may alter cell size, we report on measures of current 
densities (pA/pF), derived from dividing peak current amplitude by membrane 
capacitance (measured in pClamp) for each cell. All recordings were conducted 
on the stage of an epifluorescence microscope (E600FN - Nikon Inc., Melville, 
NY, USA) placed on an anti-vibration table. An amplifier (Axopatch 1D - 
Molecular Devices, Sunnyvale, CA, USA) in combination with an A/D board 
(Digidata 1200 - Molecular Devices) and acquisition software (pClamp 7 - 
Molecular Devices) were used for electrophysiology acquisition. Data were 
digitized at 5-10 KHz and low-pass filtered at 2-5 KHz and were quantified in 
Clampfit 7 (Molecular Devices). 
Ca2+ imaging and analysis:  Cultures were incubated in Ca2+ imaging solution 
(in mM): 145 NaCl, 2.5 KCl, 10 HEPES, 10 D-glucose, 2 CaCl2, 1MgCl2, 0.01 
glycine, pH 7.3 with NaOH for 30 min in the dark. This solution contained 2 uM 
Fura-2 AM (F1221 – Invitrogen) and was made monthly with fresh DMSO 
(0.085%) and Pluronic® F-127 (0.015%, weight/ volume). Each culture dish was 
then rinsed three times with Ca2+ imaging solution containing no indicator and 
placed in the dark for 20 min (de-esterification period). The dish was then placed 
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on the stage of the microscope. Intracellular Ca2+ transients were visualized by 
exciting Fura-2 at 340 +/-20 nm and 380 +/- 20 nm using a high-speed filter 
changer (Lambda DG4, Sutter instruments, Novato, CA, USA) to obtain a 
ratiometric value independent of indicator concentration. Emitted light was 
passed through a dichroic filter (400 nm high pass) and an emitter filter (520 +/- 
30 nm; Chroma Technology) and was digitized onto the sensor of an EMCCD 
camera (iXon-Andor Technology, Belfast, Ireland). Ca2+ transients were 
measured and analyzed using Imaging Workbench 5.0 (INDEC BioSystems 
Santa Clara, CA) as previously published [481, 482]. The greater ratio (340/ 380 
nm) values reported reflect higher Ca2+ levels. The gray value for both excitation 
wavelengths of each cell measured (region-of-interest - ROI drawn around soma) 
was background subtracted from an area devoid of cellular components. When 
imaging Ca2+ during periods of depolarization (50 mM KCl), the Ca2+ imaging 
solution was modified with a reduction in NaCl to 97 mM in order to control for 
osmolarity changes. 
Statistics: Data were analyzed using Prism 5.0 (GraphPad Software, La Jolla, 
CA, USA). Paired t-tests and repeated measures ANOVA were used to test for 
group differences with significance set at p< 0.05. For electrophysiology 
experiments, data from each recorded cell (perfusion conditions precluded 
recording 2 cells per dish) was considered a single data point (i.e., n=1). For 
Ca2+ imaging data, 5-10 cells in the field of view were averaged and considered 
a single data point (i.e., n=1). 
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4.3 Results 
4.3.1 Effect of insulin on whole-cell Ca2+currents.  
Ca2+ currents were recorded before and after a 10 mins perfusion of either 
external solution (time control; n=19), or external solution supplemented with 10 
nM insulin (n=17) using the SF77A fast perfusion system. Cells were held at -70 
mV and were stepped to the peak voltage determined from the I-V relationship. 
Peak and late currents (obtained immediately prior to termination of the voltage 
step) were quantified and are presented normalized to cell size (pA/pF). A 
significant decrease in peak (-20%; p<0.0001) and late (-31%, p<0.002) Ca2+ 
currents in response to acute insulin application was seen (Figure 1A-C). Based 
on a subset of the cells recorded (n=7 per group), there was no change in the I-V 
relationship (Figure 1D). 
To determine if the actions of insulin were selective for L-type Ca2+ channels, 
cells were held at -40 mV and stepped (350 ms) to peak voltage. Whole-cell 
recording analysis indicated that similarly to reductions seen from a holding 
potential of -70 mV, L-type-enriched Ca2+ currents were significantly reduced 
(Figure 1E and F) both at the peak (-22%; p<0.0004) and during the late current 
phase (-33%; p<0.005). The data suggest that insulin did not alter the inactivation 
rate of currents (Figure 1A), and did not show a greater inhibitory effect on 
currents elicited from -40 mV. This indicates insulin does not selectively reduce 
L-VGCCs but instead, may reduce all VGCCs. 
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Figure 4.1 Ca2+ channel currents are reduced in response to acute insulin 
application in mixed hippocampal cultured neurons. 
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A. Example of VGCC currents recorded during recording solution perfusion 
(black) and after 10 min insulin (grey) during maximal step depolarization from -
70 mV. B.-C. Quantification across groups of cells following 10 min of insulin 
perfusion (Insulin) versus recording solution perfusion (Time Control) shows peak 
and late Ca2+ currents were significantly reduced (p<0.05). D. In a subgroup of 
cells, current-voltage relationships were not significantly altered. E. Example of 
the effects of insulin on L-VGCCs recorded from a holding potential of -40 mV 
during recording solution perfusion (black) and after 10 min insulin perfusion 
(gray). F.-G. Compared to time control, recordings from -40 mV, max peak (F) 
and late Ca2+ current (G) were significantly reduced by insulin (p<0.05). The 
effect of insulin on VGCC does not appear to be L-VGCC selective. All data 
represent mean +/- SEM and are normalized to cell size (density, pA/pF), 
asterisks indicate significance at the p<0.05 level. 
 
Table 4. Patch clamping parameters. 
 
Group Cm (pF) Rm (MΩ) Ra (MΩ) HC (pA) 
Bath (n=17) 50.8 ± 3.89 432.9 ± 32.0 10.6 ± 0.85  -102 ± 8.6 
10 nM Insulin 
(n=19) 56.2 ± 3.5 415 ± 34.8 10.7 ± 0.77  -100 ± 8.7 
 
 
All data presented as means± SEM on measurements of patched neurons 
membrane capacitance (Cm), membrane resistance (Rm), access resistance 
(Ra), and holding current (HC) (control n= 17, insulin n=19). No significant 
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difference was found between control and insulin treated neurons in any 
parameters measurements (p>0.05). Comparisons made using unpaired student 
t-test. 
 
4.3.2 Effect of insulin on spontaneous Ca2+ transients.   
We then used ratiometric Ca2+ imaging to test whether insulin could alter 
spontaneous activity in cultured neurons. We used the similar experimental time 
frame as presented in Figure 1 and monitored Ca2+ oscillations during 10 min of 
Ca2+ imaging solution perfusion (time control; n=11) and during the next 10 
minutes when the solution was supplemented with 10 nM insulin (n=14). We 
show here that resting Ca2+ levels were not altered by acute insulin exposure 
(Figure 2D; p>0.05). Similarly, insulin did not change spontaneous network 
activity (no TTX) derived from measures of spontaneous Ca2+ events (Figure 2A 
– right). Those include measures of area-under-the curve (AUC; Figure 2 B; 
p>0.05), peak amplitude (Figure 2C; p>0.05), and the number of spontaneous 
events detected (Figure 2E; p>0.05) in control conditions and in insulin-treated 
experiments. These spontaneous Ca2+ transients were blocked by TTX (data not 
shown). 
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Figure 4.2 Spontaneous Ca2+ transients are not altered in response to acute 
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insulin exposure. 
 
A. Example of neurons and ROI selection (green circles and numbered arrows- 
left). Right shows the three ROIs measuring somatic Ca2+ across time. This 
approach was used to quantify changes during 10 min of imaging solution 
perfusion (Time Control) as well as during 10 min of insulin perfusion (Insulin). 
B.-E. Insulin perfusion did not change spontaneous Ca2+ activity based on 
measures of AUC, peak transient amplitude, or the number of events detected. 
Resting Ca2+ levels also were not altered by insulin. All data represent mean 
+/- SEM. 
 
4.3.3 Effect of insulin on KCl- mediated Ca2+ transients.  
We used potassium-mediated depolarization (30 s) in Ca2+ imaging 
experimental conditions to investigate the impact of insulin on overall neuronal 
Ca2+ homeostasis. This approach causes membrane depolarization with 
subsequent activation of VGCCs and Ca2+ influx through the plasma membrane, 
which in turn, activates Ca2+-induced Ca2+-release (CICR) from the 
endoplasmic reticulum through activation of RyRs [482-484]. Potassium-induced 
Ca2+ transients were reduced by 10 min of insulin perfusion (n=23) compared to 
10 min of Ca2+ imaging perfusion (time control; n=14; Figure 3A and B). 
Consistent with the results on spontaneous Ca2+ fluctuations, insulin did not 
reduce resting Ca2+ levels measured immediately prior to the depolarization 
(Figure 3D). While a trend in reduction of the peak Ca2+ transient amplitude was 
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noted in response to insulin (Figure 3C; p=0.08), measures of the AUC of the 
depolarization envelope unmasked a significant insulin-mediate reduction (Figure 
3B; p<0.0001). Notably, the reduction in the potassium-mediated Ca2+ response 
seemed to selectively reduce the delayed Ca2+ component or “hump”, present 
after the peak response (Figure 3A, bottom right). This brought to our attention a 
potential link to CICR, given that this response by nature, is often delayed 
compared to an initiating Ca2+ spike. 
 
 
 
 
 
 
91 
 
Figure 4. 3 Effects of insulin on KCl-induced depolarization. 
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A. Pseudocolored images of cells in culture during Fura-2 imaged at rest (left) 
and during peak depolarization (right). Red colors indicate greater levels of Ca2+ 
(higher ratios). Two sequential KCl depolarizations were separated by 10 
minutes of either imaging perfusion or insulin. Representative Ca2+ transients 
are shown and highlight measures of resting Ca2+, peak Ca2+ and AUC. Note 
the selective effect of insulin on reducing the late phase of the Ca2+ transient, 
essentially eliminating the “hump”. B. Ratiometric quantification during time 
control experiments or after insulin, shows the AUC resulting from KCl-induced 
depolarization was significantly decreased by insulin. C.-D. Peak ratio or resting 
ratio measures were not altered by insulin. A trend for peak ratio levels in 
response to insulin was noted. All data represent mean +/- SEM. Asterisks 
indicate significance at the p<0.05 level. 
 
 
 
 
 
 
 
 
 
 
 
 
 
93 
4.3.4 Insulin appears to reduce CICR function. 
To test whether the reduction in the “hump” during potassium-induced 
depolarization reflected inhibition of the CICR component, we used high 
concentrations of ryanodine (20 uM) which significantly reduce CICR [377, 474]. 
These experiments required three 30 s repeated potassium depolarizations each 
separated by 10 min (time control; Figure 4). To test for the impact of ryanodine 
and/ or insulin, the first depolarization was triggered after 2 min of imaging 
solution perfusion, the second depolarization occurred after 10 min of ryanodine 
perfusion, and the third depolarization was after an additional 10 min of insulin 
perfusion (Figure 4A). As shown in Figure 4A and B, blocking CICR with 
ryanodine during potassium mediated depolarization (n=10) significantly reduced 
the “hump” after the initial high amplitude transient (Figure 4B, F(2,29) = 53.8; p 
<0.0001). As consistently shown throughout our studies, time control 
experiments show no significant difference in the variables measured (n=11). 
Post-hoc analyses revealed no significant difference in the AUC obtained under 
ryanodine or insulin conditions. Thus, addition of insulin had no further impact on 
this Ca2+ plateau, indicating that high ryanodine concentration may have 
occluded the impact of insulin. The lack of an additive effect between insulin and 
ryanodine actions suggests insulin may reduce CICR by inhibiting ryanodine 
receptors.   
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Figure 4.4 Ryanodine receptors are likely targets of insulin actions. 
 
A. Three sequential KCl-mediated depolarizations were used in these 
experiments and were triggered under imaging solution perfusion (left) and 
during perfusion with ryanodine, or insulin (right). Representative ratiometric 
Ca2+ transients highlight the impact of inhibiting CICR on the “hump”. Addition of 
insulin did not further reduce the “hump”. B. Quantification across the groups of 
cells imaged shows the significant insulin-mediated reduction in the AUC as in 
Figure 3. As expected, ryanodine (Rya) also significantly reduced the “hump”, 
indicating ryanodine and insulin may both be working on inhibition of RyRs. All 
data represent mean +/- SEM. Asterisks indicate significance at the p<0.05 level. 
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4.3.5 Insulin actions occur via occupation of the insulin receptor.  
To investigate whether 1) components other than insulin in the glulisine 
formulation, or whether 2) the actions of insulin were mediated via occupation of 
the insulin receptor, we used an insulin binding peptide (i.e., affibody) and an 
anti-insulin receptor antibody, respectively. For these experiments, we used the 
same experimental protocol as presented in Figure 3 with two potassium-
mediated depolarization 10 min apart.  Either the affibody peptide (n=6-16 per 
condition) or the antibody (n=9) was used. The results are again compared to 
time controls with perfusion of imaging solution (n=16). While lower doses of the 
affibody (100 ng and 500 ng/mL) did not prevent the insulin-mediated reductions 
in the Ca2+ AUC (Figure 5A, p<0.01 and p<0.05, respectively), a higher dose (1 
ug/ml) was able to completely inhibit this effect such that the reduction in AUC 
was no longer present (p>0.05). Doses used are modelled after in vivo studies 
[485, 486]. These results suggest that the effects of insulin on hippocampal Ca2+ 
levels were mediated through insulin receptors (Figure 5B - right). 
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Figure 4.5 Anti-insulin affibody peptide and anti-insulin receptor antibody 
inhibited insulin actions on KCl-mediated Ca2+ transients. 
 
Experiments were conducted as in Figure 3, with 2 sequential KCl 
depolarizations. A. High-dose (1 ug/mL) anti-insulin affibody neutralized the 
effect of insulin on KCl-induced Ca2+ transients while lower concentrations (100 
ng/mL and 500 ng/mL) did not.  B. 500 ng/mL insulin receptor antibody also was 
able to inhibit insulin actions on the KCl-mediated Ca2+ transients. These results 
indicate the actions reported here on Ca2+ homeostasis are mediated by insulin 
working on insulin receptors. All data represent mean +/- SEM. Asterisks indicate 
significance at the p<0.05 level. 
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4.4 Discussion 
The experiments described here were intended to characterize actions of acute 
insulin exposure on neuronal Ca2+ currents and Ca2+ levels. The techniques 
used provide the most direct approach for analyses on the impact of insulin on 
hippocampal neurons without the confounding interactions of blood vessels and 
other cell types. Cultured neurons are detached from hormonal and perfusion 
influences, providing for a simplified environment where acute drug exposure is 
rapid and direct, free from the diffusion hindrance of the brain parenchyma or 
extra-neuronal interactions. Similar approaches in our lab and others have 
revealed significant connections between the actions of several hormones and 
neuronal function [474, 482]. Our results provide evidence that Apidra®, a zinc-
free insulin formulation, is able to reduce VGCC currents and Ca2+ levels 
attained during neuronal depolarization. The mechanism is dependent on insulin 
receptor activation, and also appears to engage ryanodine receptors as CICR 
contributions were reduced in response to acute insulin treatment. 
 
Ca2+ currents are a target of acute insulin in neurons 
The insulin-mediated reduction in whole-cell currents does not appear to be 
specific to one subtype VGCC. This is supported by evidence of currents 
recorded from -70 mV before and approximately 10 minutes after the addition of 
10 nM insulin, showing the same degree of inhibition for the peak and late 
currents (i.e., similar inactivation rates in Figure 1A). Furthermore, the reduction 
in currents elicited from a holding potential of -40 mV, which favors L-type Ca2+ 
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currents, was not significantly greater in amplitude when compared to the 
inhibition seen from -70 mV, arguing against a selective effect of insulin on L-type 
Ca2+ channels. Previous work on regulation of VGCC in different cell types also 
notes that the effect of insulin may not be selective for a particular type of VGCC 
(e.g., N- or L-type VGCCs; [487, 488].  
This insulin mediated reduction in VGCC was not accompanied by a shift in the I-
V relationship (Figure 1D), indicating the mechanism likely impacts flux of the 
charge carrier through the channels rather than alterations in the voltage 
sensitivity or inactivation properties of the channels.  This result is aligned with 
prior work in pinealocytes and photoreceptors, showing that tyrosine 
phosphorylation can reduce L-VGCC function [335, 407]. Evidence also suggests 
that the pore-forming alpha subunit of some VGCCs can be regulated directly by 
tyrosine residue phosphorylation [487-489].  Prior work has shown that acute 
insulin can alter other ion channels including large-conductance Ca2+-activated 
potassium channels (BK-type). Under these conditions, insulin reduced somatic 
Ca2+ levels during spontaneous oscillations in cultured hippocampal neurons 
[406]. Further, given the evidence that reductions in Src binding to the alpha 1 
subunit of the L-VGCC significantly reduces channel current amplitude in cardiac 
myocytes [490] and that insulin can reduce Src activity [491], this signaling 
pathway likely highlights a potential mechanism by which  insulin reduces VGCC 
current flux.  
Still, it should be noted that some cells respond to tyrosine kinase 
phosphorylation with enhanced VGCC function and potentiated Ca2+ levels [492, 
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493], and that given the complexity of second messenger systems working 
through many kinases and phosphatases [494], the exact impact of insulin on 
VGCC likely depends on the presence and state of activation of other interacting 
pathways (i.e., PKA, PKC, AKAP, phosphatases, etc.). Irrespective of the 
mechanism of inhibition of VGCC by insulin, it is clear that VGCC are a target of 
insulin in neurons. The effect described here, therefore, is likely to mediate the 
beneficial impact of the hormone on cognitive function following intranasal 
delivery in animal models [30, 467, 469, 470] and in early AD subjects [32, 33, 
35, 398, 401, 495]. Indeed, according to the Ca2+ hypothesis of aging and 
dementia [188, 443, 496], reducing Ca2+ levels in postsynaptic neurons is a 
favorable approach to offset cognitive decline in aging and AD (see below).  
 
Other potential targets of insulin actions 
Previous work shows insulin can increase cell surface expression of NMDA 
receptors [89] and can reduce surface expression of AMPA receptors [88, 332]. 
These studies employed similar insulin exposure time as used in the current 
study, but concentrations were 50-1000-fold higher. Thus, it is not clear whether 
transient changes in NMDA and AMPA surface expression would manifest using 
10 nM insulin in the absence of TTX. As reported in Figure 2, the nearly 
physiological insulin concentration used here does not necessarily alter network 
excitability. This is evidenced by a lack of insulin action on resting Ca2+ levels, 
peak amplitude of the spontaneous Ca2+ responses, the AUC of the 
spontaneous events, as well as the number of spontaneous events. Our work, 
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therefore, may suggest that higher concentrations of insulin are needed to alter 
network oscillations, overall excitability and spontaneous activity. Although not 
tested directly here, our results do not provide evidence that insulin can increase 
surface expression of GABAA receptors [92, 405] which should have reduced 
excitability. Within the time frame tested here (~10 minutes) and at the low 
concentration used, we did not see evidence of depression in spontaneous Ca2+ 
events (Figure 2). Thus, further studies focusing on insulin concentration-
responses and time of exposure are needed to clarify these discrepancies. Of 
course, it will also be important to address the different types of insulin 
formulations used and to include the adequate zinc controls, given that almost all 
insulin formulations are zinc-based. 
While insulin did not alter spontaneous Ca2+ activity and Ca2+ events 
amplitudes within the network of cells in culture (Figure 2), we did notice a 
significant alteration in the shape of the potassium-mediated Ca2+ responses 
following insulin treatment (Figure 3). The disappearance of the “hump” following 
the peak Ca2+ rise revealed the possibility that RyRs might be sensitive to 
insulin. We tested this hypothesis by pretreating the cultures with high 
concentrations of ryanodine to inhibit Ca2+-induced Ca2+ release (CICR). As 
shown here, ryanodine pretreatment precluded further insulin-mediated inhibition 
of the Ca2+ response to depolarization (Figure 4). This suggests insulin is 
capable of reducing CICR likely through tyrosine mediated inhibition of the RyR. 
This result is in line with prior evidence that neuronal store-operated Ca2+ 
channels (SOCCs) responsible for a small but significant secondary Ca2+ entry 
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pathway for replenishing the endoplasmic reticulum, are also a target of protein 
tyrosine phosphorylation [497]. It should be noted, however, that this result is 
contrary to what is seen in striated muscle cells, where insulin elicits an increase 
in Ca2+ release through activation of RyR [498]. Future studies are necessary to 
identify whether the different RyR subtypes can respond differently to insulin, or 
whether these effects are tissue specific, and dependent on particular signaling 
pathways. 
We suggest that the novel finding of insulin actions on CICR could be highly 
beneficial to neurons and to Ca2+ dysregulation seen in aging and/ or AD, and 
that this new target potentially offers a secondary level of protection from 
sustained Ca2+-related actions in neurons. While it is not clear that the reduction 
in the “hump” (Figure 4) may provide a neuroprotective function to neurons, the 
insulin-mediated reduction in depolarization observed during this Ca2+ envelope 
could well keep neurons engaged during periods of activation.  
Learning and memory selective actions of insulin in the brain 
Past work studying insulin function in the brain identified critical links to learning 
and memory. Whether exogenous insulin on hippocampal neurons worked 
through changes in GABA, NMDA, AMPA, or even glucose transporters, it was 
understood that insulin could have a specific and selective impact on learning 
and memory and conversely, that learning also could have an impact on insulin 
receptors [28, 499]. More recent analyses of insulin action provide evidence that 
large and diverse areas of the CNS are indeed sensitive to insulin. Previous work 
shows insulin is a dynamic hormone with a rich influence on brain function. 
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Insulin stimulates the translocation of glucose transporter-4 to plasma 
membranes of hippocampal neurons within 15-30 min [100]. This rapid process 
is likely to regulate neuronal metabolic demands and the energy needed for 
learning and memory processing. In addition, insulin enhances synaptic plasticity 
by increasing the expression of dendritic postsynaptic density scaffolding protein 
(PSD-95), a key element of postsynaptic junctions in hippocampal neurons [334]. 
Together these functions and their sensitivity to insulin undoubtedly contribute to 
improved encoding of synaptic information for the storage, and perhaps, the 
retrieval of memories. 
Equally concrete examples of the links between insulin and memory come from 
evidence that insulin can acutely reduce the hippocampal AHP, a Ca2+-
dependent hyperpolarizing potential, which maintains hyperpolarization and 
precludes action potential threshold from being reached [30, 380]. The AHP is 
larger in aged compared to young animals [184, 379, 433, 453, 476, 500, 501], 
thus reducing the amplitude or duration of this hyperpolarizing potential may help 
combat age-related memory dysregulation by allowing cells to participate within a 
functional network [502]. Indeed, it has been shown that elevating potassium 
channel activity impairs learning [503], while lowering L-VGCC reduces the AHP 
[432, 452] and enhances learning [432, 504]. Moreover, increasing cholinergic 
neurotransmission which enhances cellular excitability also can enhance learning 
[436, 505-507]. 
Still, the evidence of robust insulin actions linked to memory processes or 
processes capable of facilitating memory encoding (e.g., metabolism, blood 
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flow), does not detract from the traditional role of insulin in homeostasis [508, 
509]. Indeed, it is becoming very clear that once insulin in the brain, the hormone 
is not limited in function to a single or even a few target areas [366, 510], 
strengthening its position as a potential therapeutic target which requires greater 
research emphasis. 
 
4.5 Conclusions 
We used imaging and electrophysiology techniques to show that zinc-free insulin 
could have rapid and selective effects on Ca2+ sensitive functions in neurons, 
and that the effects are dependent on insulin activating the insulin receptor 
(Figure 5). This clearly engages a series of intracellular signals that through 
uncharacterized pathways or mechanisms, lead to rapid Ca2+ reductions during 
neuronal depolarization. Clearly, more research will need to be conducted to fully 
characterize the mechanism underlying this phenotype and to address the 
selectivity of the effect using different insulin formulations. Importantly, we remark 
that reducing Ca2+ dysregulation in brain aging, AD and in neuronal cultures has 
generally been associated with positive and neuroprotective outcomes, from 
improving cognitive functions to reducing cellular toxicity. We present evidence 
here that insulin could well be an endogenous modulator of these functions.  
Reductions in insulin levels or in insulin signaling in the brain during aging and in 
AD may highlight one of the mechanisms that could reduce metabolism, thereby 
reducing cognitive function. However, our results also suggest that replacing 
insulin or enhancing insulin signaling in the brain of aging, or early AD subjects 
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may be a valuable approach. We emphasize that the novel impact of insulin on 
neurons presented here could well underline the beneficial impact of intranasal 
insulin on cognitive enhancement in the clinic and in animal studies. If insulin is 
able to reduce Ca2+ levels in vivo, the noted reductions in insulin-sensitive Ca2+ 
responses may offset brain aging processes and ultimately, offset the impact of 
dementia on brain function.  
 
 
105 
Chapter 5 Discussion and conclusion 
 
The data collected for this dissertation project is presented in the form of two 
manuscripts. The purpose was to test the hypothesis that intranasal insulin could 
offset cognitive decline in aged animals and to characterize the impact of insulin 
on neuronal calcium status. The first manuscript (see chapter two) has been 
published in the Journals of Gerontology Series A in 2016 [30] and the second 
manuscript (see chapter four) has been submitted to Neuroscience (Maimaiti et 
al., 2017).  
 
5.1 Effects of insulin on memory and Ca2+-dependent AHP 
In the first study, to test whether intranasal insulin could reverse aging-related 
memory decline, we used the Morris water maze, a hippocampal dependent 
spatial learning and memory task, to evaluate insulin effects on memory in young 
and aged F344 rats. Aged animals were divided into five groups; each group 
repeatedly received saline, a low dose of Humalog® and a low, medium, and 
high dose of Levemir®.  Also, the young control group received saline, used as a 
normal young baseline. The behavioral study results showed that intranasal 
administration of two different formulations of insulin (Humalog®, a short-acting 
insulin analogue, or Levemir®, a long-acting insulin analogue) reversed the 
memory decline in aged F344 rats compared to aged rats in the saline controls. 
We found that while a low dose of Humalog® and Levemir® enhanced the 
memory, a medium dose of Levemir® worsened the memory, and a high dose of 
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Levemir® did not change the memory. Therefore, it is clear that selective doses 
and formulations of insulin have beneficial effects on the memory in the aged 
animals. In addition, controversial clinical study results exist regarding insulin 
dosages and formulations for use in AD patients. In animal and clinical studies, 
different dosages and formulations of insulin have various outcomes. These 
varied results led to further investigation of the underlying mechanisms 
responsible for intranasal insulin’s beneficial effects on memory as seen in select 
animals and human studies, highlighting the importance of enhancing insulin 
action in the brain. 
So far, three main methods (insulin sensitizers, intravenous insulin infusion, and 
intranasal insulin) have been used for increasing brain insulin levels. Due to the 
poor permeability of insulin sensitizer (Thiazolidinedione) to the blood brain 
barrier [511, 512], and the high risk of hypoglycemia from intravenous insulin 
infusion (see chapter three), however, intranasal insulin appears to be the best 
method to increase brain insulin levels. Nevertheless, the underlying 
mechanisms responsible for intranasal insulin’s positive effects are still poorly 
understood. One mechanism responsible for memory decline with aging is 
hippocampal Ca2+ dysregulation. 
It has been more than 30 years since researchers have focused on Ca2+ 
dysregulation in the aging brain, which is measured by recording Ca2+-
dependent afterhyperpolarization (AHP) in the hippocampus neurons. Therefore, 
we examined the effects of insulin on Ca2+-dependent AHP, one of the well-
known mechanisms that increases with aging and contributes to memory decline. 
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Our results show that treatment of hippocampal slices with insulin reduced Ca2+-
dependent AHP in hippocampal neurons to the levels seen in young neurons. It 
is well documented that Ca2+-dependent AHP (a key biomarker of brain aging) 
increases in aged, and memory-impaired animals [30, 184, 377, 379, 380, 432-
434]. Thus, insulin-mediated reduction in Ca2+-dependent AHP may be 
responsible for some of the beneficial effects of insulin on cognition.  
Most insulin formulations were designed by combining insulin with zinc. In fact, 
zinc itself plays a vital role in the physiological functions of cells, and is like Ca2+, 
an essential ion to regulate intracellular signaling. Therefore, it is important to test 
insulin and zinc effects separately on brain Ca2+ regulatory processes. Thus, 
when the effects of Apidra® (fast acting zinc-free human insulin) and zinc on the 
AHP were tested separately, both were found to reduce the AHP. Therefore, we 
used the zinc-free human insulin Apidra® to study specific insulin actions in 
hippocampal neurons without the influence of zinc. 
The next question we asked was how does insulin reduce the Ca2+-dependent 
AHP? The greater AHP seen in aged memory-impaired animals positively 
correlated with elevated intracellular Ca2+ concentration. This alteration results 
from increased Ca2+ influx via voltage-gated Ca2+ channels and Ca2+-induce 
Ca2+-release via RyRs (see chapter three). Conversely, it is possible that a 
reduction in AHP with insulin treatment may mediate through the reduction in 
intracellular Ca2+ levels via VGCCs and RyRs. 
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5.2 Whole-cell patch clamping and Ca2+ imaging in hippocampal neurons 
In the second manuscript, we aimed to identify the effects of insulin on 
hippocampal Ca2+ levels in cultured neurons. The significance of this data is 
showing that insulin reestablishes hippocampal Ca2+ homeostasis.  Aging and 
AD animal models have shown that elevated intracellular Ca2+ levels in the 
hippocampus contribute to poor spatial memory [180, 453]. Reestablishment of 
intracellular Ca2+ homeostasis might be one of the possible neuronal 
mechanisms responsible for the beneficial effects of insulin on cognition. Two 
main sources of intracellular Ca2+ are Ca2+ influx through voltage-gated Ca2+ 
channels on the plasma membrane and internal Ca2+ efflux from the 
endoplasmic reticulum via ryanodine-mediated Ca2+ release in the 
hippocampus. It is well documented that both voltage-gated Ca2+ channels and 
ryanodine receptors undergo functional changes with aging and that lead to 
elevated intracellular Ca2+ levels, which is toxic for neurons (see chapter three). 
It is widely accepted that reducing the elevated intracellular Ca2+ levels is one of 
the established approaches to improving memory in the aging and AD population 
[377, 435, 453]. Therefore, insulin effects on both voltage-gated Ca2+ channels 
and ryanodine receptors were tested. Insulin affected two main intracellular Ca2+ 
sources, including Ca2+ influx via voltage-gated Ca2+ channels and RyRs-
mediated Ca2+ release. After 10 minutes of insulin perfusion to patched single 
neurons, whole-cell patch clamp recording results show that both VGCCs and L-
type VGCCs currents decreased in hippocampal neurons. We found that acute 
insulin perfusion to neurons resulted in the same level of reduction in both 
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VGCCs and L-VGCCs. This data suggests that insulin uniformly affects all type 
of voltage-gated Ca2+ channels. It is well documented that an elevated 
intracellular Ca2+ results from increased L-VGCCs, which has been linked to 
memory decline in aged animals (see chapter three). Therefore, insulin-mediated 
reduction in Ca2+ influx via this channel may be an underlying mechanism 
partially responsible for insulin’s memory-enhancing effects seen in animal and 
clinical studies. In addition, Ca2+ imaging data show that acute insulin perfusion 
did not change resting Ca2+ transients, and significantly reduced ryanodine-
mediated Ca2+ transients. Intracellular Ca2+ concentration is amplified due to 
enhanced ryanodine-mediated Ca2+-induced Ca2+-release from the 
endoplasmic reticulum in animal models of aging and AD [377, 435, 513]. 
Reduction in RyRs-mediated Ca2+ transients may underlie neuronal 
mechanisms responsible for positive actions of insulin in hippocampal neurons.  
Furthermore, this result indicates that RyRs inhibitors will improve the memory in 
AD patients.    
 
5.3 Insulin improves memory by regulating intracellular Ca2+ levels 
Together, these two studies combine intranasal insulin approaches, 
hippocampal-dependent memory and learning task, sharp electrophysiology, 
whole-cell patch clamp, spontaneous and depolarization mediated Ca2+ imaging 
to highlight potential neuronal mechanisms of insulin-mediated cognitive 
improvement seen in clinical studies. We show that hippocampal Ca2+-
dependent AHP, voltage-gated Ca2+ channel currents, and Ca2+ transients are 
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increased in aged rats—all major factors influencing memory decline with 
aging—are significantly reduced by insulin treatment. Furthermore, this reduction 
in voltage-gated Ca2+ channel currents and ryanodine-mediated Ca2+ transients 
were correlated with reversal of Ca2+ dysregulation and memory impairment 
observed in aged rats.   
These study results support the concept that brain insulin resistance/ deficiency 
present in aged, diabetic and AD models of rats could be a major contributor to 
aging-related cognitive decline.  Indeed, increasing brain insulin levels using the 
intranasal route improves memory by reducing AHP via regulating intracellular 
Ca2+ levels. Thus, taken together, these findings suggest that insulin is a key 
hormone influence over neuronal Ca2+ regulation and strengthen the brain 
insulin-deficiency mechanistic hypothesis of pathological aging.  
 
5.4 Aging-related changes in memory and hippocampal Ca2+ levels  
Insulin treatment reversed both aged-related memory decline and Ca2+ 
dysregulation in hippocampal neurons. It has been decades since our lab and 
others have focused on the relationship between cognitive decline and increased 
Ca2+ dysregulation in aged animals [30, 224, 433, 435, 514]. Ca2+ dysregulation 
means elevated intracellular Ca2+ concentration, that gives rise to a larger AHP 
in aged animals and is considered one of the neuronal mechanisms underlying 
memory decline with aging. In addition, researchers identified pharmacological 
agents such as Ca2+ channel blockers (inhibiting the elevation of intracellular 
Ca2+ concentration) that reduce the amplitude and duration of the AHP to 
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improve cognitive function in aged animals [515]. Furthermore, previous studies 
from our research group using gene transfer approaches to increase and/or 
decrease FKBP1b (a small immunophilin that stabilizes RyR-mediated Ca2+ 
release) expression in the hippocampus showed a similar correlation between 
memory impairment and Ca2+ dysregulation [435]. In the present study, we 
found a consistent association between age-related changes in hippocampal-
dependent memory, and Ca2+ levels. Most importantly, insulin treatment 
improved memory in aged rats, reduced the AHP, Ca2+ channel currents, and 
Ca2+ transients. Insulin in the brain may be a key element for maintaining 
hippocampal Ca2+ homeostasis and cognitive function during aging.  
 
5.5 Potential relevance to healthy and pathological aging 
Biologists suggest that brain function starts to decline from the third decade of life 
leading to either healthy or pathological aging, suggesting that some changes in 
natural brain aging give rise to pathological neurodegeneration and AD. These 
changes include brain insulin deficiency and loss of neuronal Ca2+ homeostasis. 
Disruption of brain insulin signaling contributes to the AD clinical symptoms 
(memory impairment) and pathology [137, 149]. In addition, increased 
intracellular Ca2+ concentration from the dysfunction of VGCCs and RyR 
receptors markedly influence neuronal survival, communications, and function, 
which have been considered major risk factors for AD [185, 435, 516, 517]. 
Conversely, brain-specific enhancing insulin signaling improved cognitive 
function in selective AD patients, and improved memory in experimental aged 
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animals. In addition, our study results show that intracellular Ca2+ levels 
decreased with insulin treatment in hippocampal-cultured neurons. Importantly, 
brain insulin deficiency during aging together with other factors may accelerate 
Ca2+ dysregulation and stimulate amplification of intracellular Ca2+ levels, 
increasing the vulnerability of AD. Thus, studies presented here support that 
increasing brain insulin levels may be a vital approach for promoting healthy 
aging and, possibly, reversing cognitive decline present in aging and AD 
populations.  
 
5.6 Study limitations 
In the second study, all the whole-cell patch clamping and Ca2+ imaging data 
were obtained from the hippocampal cultured neurons in response to acute 
insulin treatment. Cells in culture are not expose to same multitude of signals 
environment that is present in functional human body. Thus, those data cannot 
directly translate into a clinical AD study. However, it provides potential 
mechanisms for insulin actions on hippocampal neurons. Primary hippocampal 
cultured neurons have been used as a valid model for studying the neuronal 
molecular mechanisms underlying the age-related changes in Ca2+ channels 
and neuronal survival [439], as well as for visualizing protein expression, 
trafficking, and localization [518]. We used primary hippocampal cultured 
neurons to study insulin action on hippocampal Ca2+ levels. Intracellular Ca2+ 
homeostasis is important for proper neuronal function throughout life, and it 
influences a wide range of neuronal development processes, including 
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formation of neurotransmitters, ion channels, neurite outgrowth, 
synaptogenesis, and intrinsic firing patterns [519-522]. Intracellular Ca2+ 
homeostasis is dependent on the proper function of voltage-gated Ca2+ 
channels on the plasma membrane and ryanodine receptors on the 
endoplasmic reticulum. In addition, both these channels have shown functional 
changes during aging. The voltage-gated Ca2+ channel density increases with 
aging, and this negatively correlates with neuronal survival in cultured 
hippocampal neurons [439]. Hippocampal neurons in the primary culture 
undergo time-dependent development and changes as well [183, 523]. From 
day in vitro (DIV) 1 to DIV 6, neurons rapidly attach to the dish, grow, and 
establish networks. From age DIV 10 to DIV 28, unhealthy and dead neurons 
increase as a function of age in the culture. In addition, a whole-cell Ca2+ 
currents recording from hippocampal neurons at different ages in the culture 
show that Ca2+ current density increases as neurons are aged in the culture 
[439]. Hippocampal cultured neurons help us to study the effects of insulin on 
hippocampal neurons in a single isolated environment that eliminates other 
factors. Thus, hippocampal cultured neurons seem to be an appropriate model 
for studying the link between insulin and hippocampal Ca2+ levels.  
As I mentioned earlier, Ca2+-dependent AHP depends on both Ca2+ and K+ 
ions. In my dissertation, I focus only on the Ca2+; therefore, the K+ component 
still needs to be studied. Therefore, those data partially explain the mechanism 
of insulin actions on the AHP and memory.  
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5.7 Future directions 
These studies have shown that insulin reduces the Ca2+-dependent, K+-
mediated slow afterhyperpolarization (sAHP), reduces the VGCCs currents, and 
reduces RyRs-mediated Ca2+ transients. This study provided a clear link 
between insulin and intracellular Ca2+ concentration (mainly through voltage-
gated Ca2+ channels and RyRs mediated Ca2+-induced Ca2+-release) in 
hippocampal neurons. However, the effects of insulin on potassium channels in 
hippocampal neurons in the context of cognitive functions have not yet been 
studied. There are a few studies showing a connection between insulin and 
potassium channels in the kidney [524] but not in the brain. In fact, “Ca2+-
activated K+ channels play an important role in the control of neuronal 
excitability via the generation of the AHP” (Davies et al., 2006). Furthermore, 
earlier studies suggest that potassium channels contribute to the generation of 
sAHP in hippocampal CA1 neurons [525-529]. In addition, potassium channels 
undergo functional changes with aging and influence neuronal function and 
sAHP [530, 531]. From these findings arose the idea that insulin may be able to 
rebalance potassium channel functions, which may further reduce amplitude 
and duration of the sAHP. Other graduate students in the lab could look at the 
relationship between insulin and potassium channels in the hippocampal 
neurons.  
Earlier research intensely focused on RyRs’ role in heart and skeletal muscle 
excitation-contraction. Some studies suggest that the cardiac ryanodine 
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receptor (RyR2) is a promising drug target for treating arrhythmogenesis [532]. 
Moreover, RycalsTM is a drug available on the market to inhibit cardiac and 
skeletal muscle specific RyRs [533]. In addition, dantrolene, an RyRs blocker, is 
a widely used drug to treat malignant hyperthermia in clinic. This dissertation 
showed that insulin reduced the RyRs-mediated Ca2+ transients in 
hippocampal neurons. This data suggests that the inhibition of RyRs channels 
positively correlates with memory improvement in aged animals. Therefore, 
RyRs’ role is not limited to the periphery, but also plays a vital role in the brain in 
the context of memory. Specifically, in the hippocampal, RyRs plays an 
important role in regulating intracellular Ca2+ levels and maintaining cognitive 
function [435, 453]. A few researchers are promoting the idea that 
hippocampus-specific RyRs inhibition is a therapeutic target for AD. 
Furthermore, this study strongly supports the hypothesis formulated by Dr. 
Grace Stutzmann that RyRs blockers are an effective anti-AD therapy. Thus, 
RyRs could be a drug target for inhibiting pathological intracellular Ca2+ leaks in 
the hippocampal neurons, and, more importantly, for reversing Ca2+ 
dysregulation and memory impairment with aging and AD. 
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